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Heparin is a complex mixture of sulfated polysaccharides derived from animals and 
one of the oldest drugs in use. While an efficacious anticoagulant, heparin is beset by 
side effects and pharmacokinetic difficulties. Low molecular weight heparins (LMWH) 
are made by depolymerizing unfractionated heparin (UFH) and have made 
improvements in these areas.  However, they still retain a phenomenally high level of 
complexity due to their polydispersity and the introduction of non-native structural 
features. This makes the structural characterization LMWHs a daunting task. 
This work details the development of a novel capillary electrophoretic (CE) method 
for fingerprinting LMWHs. Since their complexity normally results in a nearly featureless 
electropherogram, polyalkylamines were used as a resolving agents to yield highly 
resolved and reproducible fingerprints characteristic of the LMWH being investigated. 
 xv
Linear polyamines of resolved LMWH in a manner dependent on chain length and 
charge density, while cyclic polyamines were incapable of resolution. Longer length 
glycosaminoglycans such as UFH and chondroitin sulfate were not successfully 
fingerprinted as they lacked run to run consistency. Further investigation into the mode 
of polyamine binding showed that they bound to LMWH via a two site binding model, 
indicating the presence of specific sites on LMWH that tightly bind polyamines. Upon 
the saturation of these sites, the polyamines continue to interact via general 
electrostatic binding. Pentaethylenehexamine was also able to separate the known 
contaminant oversulfated chondroitin sulfate from UFH. 
In July of 2010, the US food and drug administration approved a generic for the 
widely used LMWH enoxaparin, a questionable move due to the difficulties of proving 
the equivalence of such a complex mixture. A comparison of the brand and generic 
batches of enoxaparin using the fingerprinting method revealed striking similarities, 
bolstering the generic’s claim of equivalency and providing a protocol for the evaluation 
of other biosimilar LMWHs. 
This is the first work utilizing CE in developing high resolution fingerprints of LMWH. 
It presents a noteworthy method for quality assessment of LMWH and provides the 
basis for designing other small molecule probes for the analysis of complex 
glycosaminoglycans.  
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Introduction 
 
1.1 The Structure, Source, and Pharmacological Properties of Heparin 
Heparin is a heterogeneous, polydisperse, highly sulfated natural polysaccharide 
that is widespread among species ranging from invertebrates, such as shrimp and 
clams, to mammals, such as cows and humans [1-2]. Part of the larger family of 
carbohydrates, known as glycosaminoglycans (GAGs), it is the oldest anticoagulant in 
use and one of the longest serving pharmaceuticals [3]. Along with its closely related 
cousin heparan sulfate (HS), it has been shown to interact with a myriad of proteins 
such as antithrombin, granulocyte-colony stimulating factor, fibroblast growth factors, 
chemokines such as interleukins, cellular adhesion proteins such as selectins and 
fibronectin, pathogen proteins from herpes-simplex and human immunodeficiency 
viruses, and many others [4-6]. The structural diversity of heparin and HS makes them 
among the most difficult substances to analyze, but also gives them a rich biological 
profile as evidenced by the numerous review articles detailing heparin/HS interactions 
with proteins that have been published to date [2,4,6,7]. These promise much in the 
area of drug discovery [7]. 
The biosynthesis of these polymers differs enormously from that of proteins in 
that there is no template that codes for them. Instead, the synthesis of heparin, HS, and 
related sugars is carried out by a  host of enzymes that yield a complicated mixture of 
molecules. The synthetic process begins with the building of a specific tetrasaccharide 
sequence on a serine residue of a core protein. In the crucial step that follows, an 
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acetylated glucosamine (GlcNAc) is added to the tetrasaccharide, ensuring that the 
resulting molecule will be heparin or HS rather than another GAG. The chain is 
extended by adding glucuronic acid (GlcA) and GlcNAc in an alternating manner by the 
work of GlcA/GlcN transferases, with GlcNAc(1→4)GlcA as the sequence. This is 
followed by the  N-deacetylation and subsequent N-sulfation of GlcNAc and then by the 
epimerization of many glucuronic acids to iduronic acid by C-5 epimerase.  Finally, 2-O, 
3-O, and 6-O sulfotransferases extensively sulfate the sugar, making it one of the 
strongest acids in nature. However, none of these enzymes modify the GAG backbone 
to completion or in an equivalent manner. The resulting hodgepodge, appropriately 
called unfractionated heparin (UFH), is a mixture of millions of structurally distinct 
polysaccharides with an average molecular weight of ~15 kDa and an average chain 
length of ~50 residues when harvested, yielding a astonishingly heterogeneous and 
polydisperse mixture of molecules [6,8,9].   
While heparin and HS are closely related, there are a number of key differences 
between them. First, heparin chains are freed from the proteoglycan core by endo-β-D-
glucuronidase after synthesis and are subsequently stored in the granules of mast cells 
along with various positively charged proteases and histamine. In contrast, HS is found 
on the surfaces of many cells and interacts with many proteins in the body [4,5]. HS is 
also larger then heparin with a molecular weight range of 5-50 kDa and an average of 
30 kDa, while heparin ranges from 5-40 kDa with an average of 12 kDa. Heparin is 
extensively sulfated and most glucuronic acid residues are converted to iduronic acid 
during synthesis (~90%,) while HS is less sulfated with a lesser degree of 
epimierization.  Thus, HS is more complex than heparin, having a higher degree of 
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polydispersity and heterogeneity [5,9]. Related GAGs include chondroitin sulfate (CS), 
dermatan sulfate (DS), and Keratan sulfate (KS), and hylauronic acid that differ from 
heparin with relation to sugar conformation and composition, degree of sulfation, the 
type of linkages between sugars, molecular weight, their location in the body, and their 
functions. Representitive structures of several GAGs are pictured in figure 1 [6].  
 Heparin was discovered almost a century ago and began to see use as an 
anticoagulant in the 1930’s [10]. Since then much has been discovered with respect to 
the structure and mechanism responsible for this activity. Heparin inhibits blood 
coagulation by binding to a highly positively charged site on antithrombin, a serpin, 
specifically by a sequence known as the H5 pentasaccharide. While antithrombin is 
always present in the blood, it is relatively inactive. The binding of H5 causes a 
conformational change in the serpin that increases its ability to inhibit by several 
hundred fold a number of coagulation proteases, but most notably factor Xa and factor 
IIa (thrombin). This maintains normal hemostasis by preventing unwanted thrombosis 
[11]. 
 UFH’s longevity is a testimony to its therapeutic efficacy, but it is not without 
problems. The drug exhibits irregular pharmacokinetics due to extensive protein binding 
which makes routine monitoring of activated partial thromboplastin time (aPTT) 
necessary if therapeutic anticoagulation is to be acheived and maintained. UFH and 
may also cause osteoporosis with long term use [12]. The most alarming problem with 
UFH is heparin-induced thrombocytopenia (HIT). HIT manifests itself by a precipitous 
drop in platelets and is caused by antibodies that form against heparin-platelet factor 4 
complexes. While it is an efficacious anticoagulant, these drawbacks make UFH an 
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expensive and often risky drug to administer and largely limit its use to inpatient 
settings. 
1.2  The Structure and Pharmacological Properties of Low Molecular Weight 
Heparin 
Low molecular weight heparins (LMWH) were developed in the 1990’s by 
depolymerizing UFH by various methods to yield a mixture of compounds between 
2,000 and 9,000 daltons.  While they share many chemical and therapeutic features 
with UFH, LMWHs are distinct in a number of ways. They inhibit factor Xa to a greater 
extent than thrombin because longer GAG chains are needed for this to occur [13,14]. 
LMWHs generally exhibit better pharmacokinetics due to less binding to plasma 
proteins and platelets resulting in substantially fewer monitoring requirements. Less 
binding to proteins, platelets, and osteoblasts decreases many of the undesirable side 
effects, such as HIT and osteoporosis [12,13]. The risk of bleeding between LMWH and 
UFH is similar as shown in a recent meta-analysis comparing UFH and enoxaparin in 
patients receiving deep vein thrombosis (DVT) prophylaxis [15]. These features 
represent a significant improvement over UFH and their prominence in the prevention 
and treatment of venous thromboembolic disease and is even used in outpatient 
settings [16,17].  
One thing that has long been apparent concerning LMWHs is the diversity that 
exists between varying brands and formulations. This diversity is determined by a 
number of factors including: 1)  the source of the crude heparin extract, 2) the quality 
and rigor of the post extraction purification yielding clinical UFH, 3)  the method by 
which UFH is depolymerized to yield LMWH.  The latter is the most critical in 
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contributing to LMWH identity and in the introduction of novel structural features [2]. The 
three brands of LMWH available in the US are tinzaparin (InnohepTM, Mr: 4500), 
dalteparin (FragminTM, Mr:6000) and enoxaparin (Lovenox
TM, Mr:4200). Tinzaparin is 
manufactured via heparinase digestion to yield a smaller GAG chain with an 
unsaturated uronate residue on the non-reducing end. Dalteparin is formed by treating 
UFH with nitrous acid to yield LMWH molecules with a five-membered anhydromannitol 
residue at the reducing end. Enoxaparin is manufactured under basic conditions 
yielding a chain with an unsaturated uronate residue in a manner similar to tinzaparin 
but with chains also containing a 1,6-anhydromannose on the reducing end (figure 2) 
[2,18,19]. Because our ability to analyze these complex mixtures is limited, other 
chemical features not found in UFH may also be present. This makes each brand on the 
US and  world market to be considered a distinct pharmacological entity that is not 
interchangeable according to the FDA [13]. 
The uncertainty surrounding the structure of LMWHs has come to forefront in 
recent years with the introduction of generic enoxaparin formulations. These are often 
referred to as biosimilar LMWHs [20]. Several of these have appeared around the world 
in the last decade, raising concerns over their chemical and therapeutic equivalence 
[21]. Maddineni et al. compared two generic enoxaparin formulations from India and one 
from Brazil with LovenoxTM using a battery of enzymatic, chemical, and 
pharmacodynamic tests. While the activated partial thromboplastin time and 
prothrombin time of all four were similar, the molecular weight varied from 3905 to 4339 
daltons. LovenoxTM and the Indian brands were readily digested by heparinase, but the 
Brazilian formulation was resistant to breakdown. Since these enzymes are highly 
 6
dependent on the structural nuances of heparin, its inability to degrade it indicates a 
manufacturing process that differs from that which yield the trade name product.  
The immunogenic potential of these LMWHs is also of great concern especially 
with regard to HIT. Gomes et al. compared LovenoxTM to CutenoxTM, a generic version 
manufactured by Gland-Pharma in India in an open label study in Brazil. 110 healthy 
volunteers were given 40 mg LovenoxTM and 110 were given 40 mg CutenoxTM daily for 
10 days. Interestingly, there was a slight difference in antibody composition between the 
groups at 10 days, with LovenoxTM having slightly more IgA with CutenoxTM leading to 
more IgG. While very close to one another, the differences in antibody profiles may be 
indicative of structural deviation caused by differing conditions of manufacture. It also 
raises concerns over the possibility that these LMWHs interact differently with other 
proteins in our body and lead to unforeseen side effects [22]. Since a generic LMWH 
would not be required to go through the rigorous safety and efficacy trials as the 
innovator, these may only be detected after it has seen wide usage. Yet, the cost of 
developing a new drug provides a powerful incentive to move generics onto the market. 
1.3  Current Issues in the Analysis of Heparin and Low Molecular Weight Heparin 
 In early 2008, an outbreak of hypersensitivity reactions to UFH manufactured by 
Baxter Pharmaceuticals was reported in the US. Symptoms typically began a few 
minutes from initiation of treatment and included hypotension, shortness of breath, and 
edema.  In the US, 81 U.S. fatalities were reported [23-25]. Analysis of these samples 
revealed that they were contaminated with the oversulfated chondroitin sulfate (OSCS), 
a product of the  chemical oversulfation of CS [26]. This highly anionic, non-natural 
GAG is able to mimic the anticoagulant effects of UFH and difficult to distinguish due to 
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structural similarities due to its structural similarities (figure 1a). OSCS has been shown 
to activate the plasma contact system beginning with factor XIIa. Factor XIIa is part of 
the intrinsic coagulation pathway, but also converts prekallikrein to kallikrein when 
activated.  Kallikrein stimulates the production to bradykinin, a powerful vasodilator and 
inflammatory promoter [23,27,28]. This tragedy has spawned the development of a wide 
spectrum of analytical techniques for the detection of OSCS in heparin and has 
prompted the FDA to revise its analytical protocol [29,30]. Given the complex nature of 
UFH and the possibility of other contaminants, the need for rapid, high powered 
protocols for heparin analysis is likely to continue. 
 On July 23, 2010 the food and drug administration (FDA) approved the first 
generic version of enoxaparin for the US [31]. Manufactured by Momenta 
Pharmaceuticals and marketed by Sandoz, it was approved by the FDA from an 
abbreviated new drug application and did not undergo the extensive clinical trials of the 
innovator product. Instead, the FDA examined physiochemical properties such as 
molecular weight distribution, disaccharide composition, and the presence of the 1,6-
anhydromannose ring. In addition, “the FDA required not only biological and 
biochemical assay data to demonstrate equivalent anticoagulant activity in vitro and in 
vivo but also pharmacodynamic data from healthy human volunteers.” [32] While 
achieving equivalence in these areas is notable, the fine structure of the drug remains a 
mystery. 
 The staggering chemical complexity of heparin means that there are boundless 
opportunities for biochemical studies. The 2008 contamination crisis along with the 
development and approval of generic LMWHs has created a renewed sense of urgency 
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in developing robust methods for the detection of contaminants and characterization of 
the GAGs themselves. Nuclear magnetic resonance (NMR) methods, various 
spectroscopic techniques, electrophoretic protocols, chromatographic methods, mass 
spectrometry, and hyphenated techniques have appeared in increasing number. What 
follows in sections 1.4-1.7 is a survey of the techniques used in the analysis of UFH and 
LMWH with special attention to the fingerprinting of and purity of these drugs. Emphasis 
is given to the ease of use of the assay, the time required to complete it, the cost of 
equipment and materials, sensitivity, specificity, and overall usefulness of the methods. 
1.4 Nuclear Magnetic Resonance of Heparins 
Nuclear magnetic resonance (NMR) spectroscopy has been extensively used to 
characterize heparins, Proton NMR (1H-NMR) was the first to be used to probe the 
sugar backbone and the functional groups that decorate it in the 1960’s [33,34]. In 
addition to 1H-NMR, 13C-NMR and various 2-dimensional NMR methods have given us 
substantial insight into GAG structure, meaning that  NMR has been utilized in the study 
of heparin far more than other spectroscopic techniques such as infrared or raman. 
Disaccharides obtained after enzymatic digestion of heparin were first characterized by 
1H-NMR in 1971 by Perlin and Mackie [35]. Since then, 13C-NMR and 2-D NMR 
techniques including heteronuclear multiple quantum coherence (HMQC) [36], 
correlation spectroscopy (COSY),  total correlation spectroscopy (TOCSY), nuclear 
overhauser enhancement spectroscopy (NOESY), and  rotating frame nuclear 
Overhauser enhancement spectroscopy (ROESY), have confirmed the structures of 
these GAG building blocks as well as oligosaccharides [37-39]. These powerful 
techniques have enabled elucidation of the structure of many heparin oligosaccharides, 
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but efforts are hampered by the inherent randomness of sulfation and chain length. The 
most extensive effort to characterize heparin oligosaccharides was performed by Pervin 
et al. in 1995. This mammoth effort involved depolymerizing and fractionating massive 
amounts of heparin to yield 50 grams of oligosaccharides of Mw<5,000. Fourteen 
homogeneous GAGs were isolated ranging from disaccharide to tetradecasaccharide 
and characterized using COSY. However, the internal uronic residues were 
distinguishable only up to octasaccharide length sugars [35]. Given that heparin 
contains chains far larger than tetradecasaccharide, even the most powerful NMR 
techniques would be unable to establish the structures of full length heparin chains even 
if purified to homogeneity. 
Though NMR was previously shown to detect contaminants in heparin 
preparations [40-42], the 2008 heparin contamination crisis has brought NMR into fresh 
focus.  Rather than complete structural elucidation, efforts have been focused on 
identifying glycosaminoglycan contaminants in UFH by observing subtle differences in 
NMR spectra. Most analyses since 2008 have relied on the presence of a downfield 
shift of the N-acetyl signal in 1H-NMR. This results due to the change in electronic 
character of the local carbon as a result of the increase in negative charge. Guerrini et 
al. was the first to identify the OSCS contaminant in 2008 using 1H-NMR. The 
contaminating OSCS was differentiated from UFH and the natural impurity DS by a 
downfield shift of the N-acetyl signal from 2.04 to 2.16 ppm in the 1H-NMR spectrum. 
DS showed a chemical shift of 2.08 [26]. This confirmed the work previously published 
by Maryuna et al. in 1998 [43]. Since then, the results of more than one hundred 
heparin batches have been tested [44,45,30]. Beyer et al. quantitatively determined the 
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amount OSCS and DS present in 108 samples of UFH with OSCS having an LOD of 
0.1% of a 25 mg sample of UFH [44]. The protocol has been applied to crude UFH and 
to the active pharmaceutical ingredient (API) [46]. It should be noted that many other 
peaks beside the N-acetyl signal are indicative of OSCS contamination, but their 
proximity to other signals makes reliable distinction difficult especially at low OSCS 
concentrations [44,45]. The robustness and low limit of detection of this method caused 
the FDA and U.S. Pharmacopia (USP) to mandate the use of 1H-NMR in the testing of 
individual UFH batches [29,30].  
1H-NMR has also been coupled to other powerful analytical and chemometric 
techniques. In 2005, Korir et al. characterized a pair of dissacharides and a 
tetrasaccharide with tandem capillary electrophoresis-NMR (CE-NMR) using capillary 
isotachophoresis, a mechanism allowing for sampe . Though the large amount of 
sample required for NMR makes CE-NMR largely impractical at this point, further 
technological advances may allow them to regularly be used in tandem [47]. Limtiaco et 
al. used weak anion exchange high performance liquid chromatography (HPLC) 
coupled to 1H-NMR to study OSCS, UFH, CS, and DS. Run conditions were optimized 
to allow for a nearly 8 minute baseline separation of OSCS and UFH using a 0.1-1 M 
NaCl gradient. Using D2O based buffer, distinctive on flow 
1H-NMR profiles of UFH and 
OSCS could be acquired. Stopped flow NMR allowed the GAGs a much longer 
residence in the flow cell and yielded a far more detailed spectra in which many peak 
assignments were possible for UFH, CS A, DS, and OSCS with enough resolution and 
sensitivity to assign protons from within and in between individual sugars. Additional 
sensitivity was gained  by repeatedly injecting OSCS contaminated UFH samples into 
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the column. Since UFH eluted at 0.6 M NaCl and OSCS at 0.8 M NaCl, the UFH was 
washed away after each injection and the OSCS was retained on the column. After 10 
injections, the concentrated OSCS was eluted using 0.8 M NaCl and analyzed using 
flow NMR to yield highly resolved spectra.  HPLC-NMR has the potential to signal the 
presence of impurities in UFH as well as identify them even when present in small 
amounts [48].  
Data from 1H-NMR has also proven useful in chemometric analyses [44,49-52]. 
Zang et al. utilized several techniques including principle component analysis (PCA) 
and partial least squares discrminant analysis (PLS-DA). PCA is a method for reducing 
large numbers of variables into a smaller number of “principle components” that account 
for variation. The component accounting for the most variation in the sample is 
designated PC1, while the next is PC2 and so on. When plotted in two or three 
dimensions, enormously complex data sets can be analyzed using only a few variables. 
PCA was able to sharply distinguish UFH and OSCS, but not DS.  PLS-DA provided 
even better seperation and could predict the presence of significant amounts of OSCS 
in test samples with few misclassifications [51].  
Two dimensional NMR and 13C-NMR were instrumental in chemically identifying 
the heparin contaminant in 2008. Seven peaks unique to OSCS were seen in the 
contaminated UFH using 13C-NMR while HMBC and HSQC identified oversulfated 
monosaccharides [26]. Diffusion Ordered Nuclear Magnetic Resonance Spectroscopy 
(DOSY) has been used to characterize LMWH and UFH formulations and distinguished 
OSCS in LMWH [54,55]. DOSY makes use not only of 1H-NMR chemical shifts, but the 
ditransaltional diffusion coefficient (Dt in m
2/s) which is dependent on molecular weight 
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rather than structural subtleties. Since OSCS chains are on average much larger than 
LMWH, the presence of this contaminant is made most apparent. Such a technique 
however, would be of little use if the contaminant were of a similar molar mass. Rudd et 
al. used 2-D correlation spectroscopy to identify a variety of oversulfated polysaccharide 
contaminants. This was done by subtracting standard UFH data sets from UFH samples 
contaminated with OSCS, oversulfated dextran sulfate, and oversulfated agarose 
sulfate, leaving the peaks characteristic of the contaminant available for unhindered 
study [56]. NOESY has also been used to identify OSCS in UFH by taking into account 
the environments of the ring protons [57].  
The power of two dimensional NMR is such that it is able to provide accurate 
structural information for GAGs far to complex for one dimensional NMR [36].  The chief 
limitation is that the complexity of GAG spectra often requires highly skilled 
interpretation. UFH and LMWH would prove much more difficult than a homogeneous 
sample because of their heterogeneity. However, it would prove most useful for 
confirming the identity of a contaminant that had been isolated especially when used 
alongside mass spectrometry. 
1.5  Other Spectroscopic Techniques in the Analysis of Heparins 
Infrared (IR) and Raman spectroscopies have been used to highlight suspected 
OSCS contaminated UFH lots using chemometric techniques [58]. Circular dichromism 
is useful in distinguishing between GAGs as it measures the absorption of polarized 
light in non-racemic samples [59]. The conformation of uronic acid in particular is 
distinguishable since glucuronic and iduronic acids are opposite enantiomers. It has 
also shown characteristic spectra of heparin when bound to different cations (Na+, Mg2+, 
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K+, Ca2+, Mn2+, Cu2+, Fe3+) [60]. Since cations other than sodium may shift the N-acetyl 
group of OSCS, NMR spectra, circular dichromism may be used in complimentary to 
NMR in explaining deviant signal shifts [61]. Circular dichromism was recently reported 
to give a clear differentiation of UFH and OSCS [62].   
Jagt et al. published one of the most innovative heparin analysis protocols using 
self assembling fluorescent receptors. The positively charged β-CD derivative heptakis-
[6-deoxy-6-(2-aminoethylsulfanyl)]-β-CD was derivatized with a number of amino and 
guanadino groups and allowed to form an inclusion complex with various lithocholic acid 
derivatives which bind with strong affinity. A number of lithocholic acid compounds 
derivatized with a quinolinium flourophore were complexed with the functionalized CD. 
The result was a complex with a dense positive charge and a fluorescent compound 
sensitive to its local environment. This work yielded a complex showing a change in  
fluorescence with OSCS that was far above UFH, LMWH, HS, DS, and CS. This work is 
of great importance in that it proves that small to medium sized molecules or complexes 
can distinguish between remarkably similar GAGs, which would be of great potential in 
detecting specific contaminants. It also provides a simple pathway for designing 
relatively complicated probes for the wider study of GAGs [63].  
1.6  Electrophoretic Analysis of Heparins 
Electrophoresis is a time tested approach for separating and studying heparin 
and heparin-like GAGs. Preparative scale agarose gels was used to separate and 
isolate four HS oligosaccharides [64]. Gradient polyacrylamide gel electrophoresis 
(PAGE) is useful in resolving heparin species with a similar degree of polymerization but 
differing internal structure and sulfation density [65]. In spite of the ubiquity of gel 
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electrophoresis in laboratories, capillary electrophoresis (CE) is used more often with 
GAGs as evidenced by the number of literature reviews in the last decade [66-68]. 
Several types of CE exist including capillary zone elcectrophoresis [66], capillary 
isotachophoresis [69], micellar electrokinetic chromatography (MEKC) [70], capillary gel 
electrophoresis [71], capillary isoelectric focusing [72], and capillary 
electrochromatography [73]. Of these, capillary zone electrophoresis (hereafter 
designated simply as CE) and MEKC are most commonly employed in the analysis of 
heparins because of their simplicity and effectiveness in seperating GAGs.[67]. 
In CE, a sample is injected into narrow, buffer filled, fused silica capillaries with 
an inner diameter of 20-100 µm and an electric field is applied that will draw the 
analytes toward the oppositely charged electrode as seen in figure 3. Figure 3a shows 
CE with basic (pH~7) in normal polarity mode. Under these conditions, the silanol 
groups on the wall are deprotonated, causing the cations of the buffer to coat to the wall 
forming an immovable “stern” layer. Ions in the layer outside of this coating are 
electrostatically pulled towards the cathode as a result of the zeta potential generated 
by the electric field when applied to the layer. Because these cations drag their shells of 
hydration, a powerful electroosmotic force is exerted in the direction of the cathode that 
is able to pull even oppositely charged molecules toward the cathode, enabling the 
separation of all ionic species and extending the length of the capillary. Under acidic 
conditions, the silanol groups are largely protonated, suppressing the electroosmotic 
force and allowing separation solely on the basis of charge-mass-ratio.  Depending on 
the charge of the analytes, either normal or reverse polarity can be used at low pH 
(figure 3b) [67,74,75]. MECK utilizes is a form of CE in which a surfactant is added to 
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the buffer at a concentration that allows for the formation of micelles. These act as a 
kind of stationary phase that differentially interacts with analytes, altering their mobility 
and enabling their separation [70]. A maintained CE instrument in capable hands is able 
to produce highly resolved electropherograms using only nanoliters of sample in a rapid 
fashion [68]. 
 Multiple CE protocols have been used to separate heparin disaccharides and 
oligosaccharides. Pervin et al. separated eight heparin/heparin sulfate dissacharides  
along with eight CS/UFH dissachardes with an unsaturated double bond and varying 
sulfation levels using reverse polarity CE with 20 mM phosphate buffer, pH 3.48, 
while13 heparin oligosaccharide standards ranging from 2-14 monosaccharides were 
separated using MECK (10 mM sodium borate, 50 mM SDS, pH 8.8, normal polarity). 
Baseline separation was achieved between the di- and tetrasaccharides with resolution 
decreasing at longer chain lengths [76]. These results were consistent with that 
obtained previously by Desai et al. for a mixture of 17 heparin chains ranging from di to 
hexasaccharide. Compositional fingerprinting of several LMWHs were also achieved, 
but only after significant depolymerization with heparin lyase enzymes [77]. Laser 
induced fluorescence [78] and copper sulfate [79] have also been employed in the 
detection of GAGs via CE.  
The resolution of intact UFH and LMWH presents a major hurdle for CE because 
of the phenomenal complexity of these mixtures since millions of GAG molecules are 
present with only infinitesimal differences. Ramasamy et al. fingerprinted four LMWHs 
using reverse polarity CE with both fused silica and neutral hydrophilic capillaries. While 
there were noticeable differences between the products, most of the GAG remained in a 
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relatively broad, featureless peak [80]. Patel et al. analyzed intact and decomposed 
dalteparin and enoxaparin using reverse polarity CE. A comparison of two batches of 
enoxaparin showed differences among the fine features of the electropherogram.  While 
enoxaparin resolution was better than that obtained by Ramasamy et al., the bulk of 
enoxaparin remained locked in a featureless peak [81].  
The heparin contamination crisis has incited great interest in electrophoretic 
protocols in detection of heparin contaminants with special focus on OSCS. PAGE was 
used to analyze heparins depolymerized by treatment with nitrous acid.  Heparin is far 
more sensitive to nitrous acid than most other GAGs including CS and OSCS because 
of the presence of numerous N-sulfate groups (as opposed to N-acetyl groups). UFH 
contaminated with 25% w/w OSCS was clearly distinguishable after nitrous acid 
depolymerization with the small UFH fragments mostly migrating to the end of the gel.  
The LOD of a 100 µg sample was approximately 0.5% w/w. Other GAGs such as DS, 
OSDS, hyaluronic acid, dextran sulfate as well as other heparinoids were also readily 
distinguishable from UFH, showing the utility of PAGE in detecting a variety of potential 
contaminants [45]. Cellulose acetate plate electrophoresis was also employed in the 
detection of OSCS and DS in UFH with a DS LOD of 0.4% [82]. The ubiquity of PAGE 
in biochemical research makes it an attractive option for separation, but resolution is 
dependent on the chemical decomposition of GAGs. 
While PAGE and cellulose acetate electrophoresis are capable of separating 
contaminants and impurities in UFH, neither is able to match the speed and resolution 
of CE in this application. The FDA published a CE protocol that was able to detect 
OSCS in UFH but only with partial resolution [83,84]. Though this protocol was later 
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replaced by strong anion exchange HPLC (SAX-HPLC), a number of subsequent 
methods were published with increasing efficiency and resolution [85]. Since then, 
several new CE protocols have been published. Wielgos et al used 600 mM phosphate 
pH 3.5 buffer with a 25 µm ID capillary with a total length of 64.5 cm. The result was a 
nearly baseline resolved electropherogram with OSCS visible as a sharp just ahead of 
UFH. Changing the counterion from sodium to lithium dramatically shortened the run 
time by nearly 75% with an LOD below 0.1 % w/w of the total amount GAG mass. 
Lithium based buffers have low conductivity relative to sodium and allow for higher field 
strengths, yielding shorter separations. However, such stellar sensitivity was only 
accomplished with extended path capillaries that are only compatible with CE systems 
manufactured by Agilent [84]. A modified version of this method was used alongside 1 
and 2 dimensional NMR to separate OSCS as well as oversulfated “tank bottom” 
material considered to be waste by-products of the UFH purification process [26].  
An improved method was published by Somsen et al. that resulted in the near 
baseline resolution of OSCS from UFH using high molarity tris buffer with an LOD of 
0.019 mg/ml for OSCS. The high concentration of tris resulted in substantial sharpening 
of the OSCS peak, making it easy to distinguish from UFH and DS and the generation 
of a very sharp peak. The method did not require an extended path length capillary and 
used a CE system from Beckman without an extended path length capillary [86]. OSCS 
and UFH were separated using a capillary loaded with polymerized β-cyclodextrin and 
the polymer Tetronic® 1107 which contains two positive charges under acidic 
conditions. The mixture of the two polymers creates a cationic pseudostationary phase 
that sulfated polysaccharides will readily interact with. The LOD for the detection of 
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OSCS was an astonishing 0.07% w/w of a 0.1 mg/ml UFH sample, the best yet 
achieved with CE [87].  
Since GAGs have low UV extension coefficients, derivitization with UV active 
substances would enable enhanced sensitivity. Quantitative CE was used for the 
resolution of galactosamine and glucosamine after acidic hydrolysis of a UFH/OSCS 
mixture and the derivitization of the monosaccharides with anthranilic acid. Since UFH 
and OSCS are composed of glucosamine and galactosamine sugars respectively, their 
detection and quantitation allowed for distinguishing between two GAGs. However, this 
was only possible if DS was previously degraded by chondroitinase since this would 
also give galactosamine and potentially sound a false alarm [88]. Other sources of 
galactosamine and glucosamine could potentially do the same.  
1.7  Chromatographic Analysis of Heparins 
 Chromatography of glycosaminoglycans has long been used in resolving and 
quantitatively separating heparin and related polysaccharides. Thin layer 
chromatography is capable of separating sulfated other GAGs from heparin [89]. Gel 
filtration chromatography was used to fractionate nitrous acid depolymerised heparin 
into long chains (MW > 3000), shorter chains such as tetrasaccharides, and 
disaccharides [90]. Paper chromatography SAX-HPLC was employed in the separation, 
quantification, and identification of tritiated disaccharides and oligosaccharides [91]. 
Strong anion exchange chromatography was used in purifying 14 oligosaccharides in 
Pervin et al’s massive study [36]. Reverse phase ion pairing chromatography acquired 
baseline separation of sugars ranging from disaccharide to tetradecasaccharide [92]. 
Hyphenated LC-MS is a an extremely effective tool for the characterization of GAG 
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mixtures since it can both separate and reveal structural information of GAGs [93-95]. 
Chromatography presents an attractive method for the separation of GAGs because of 
the diversity of media and techniques, the ability to collecti the resolved fractions, and 
the possibility of analysis via hyphenated techniques (LC-MS and LC-NMR) [47,96,97]. 
 Due to their relative ease of analysis, chromatographic studies of disaccharide 
and oligosaccharide composition derived from LMWH and UFH abound in the literature 
[92,96].  Karamanos et al resolved all the major disaccharides of heparin and heparan 
sulfate using reverse phase ion pairing HPLC with tetrabutylammonium and an 
acetonitrile gradient. As expected, heparin contains a far greater proportion of trisulfated 
disaccharide (68%) than heparan sulfate (8.7%).  In comparison, the depolymerization 
of dalteparin by heparin lyases yielded 84.2% trisulfated disaccharide [98]. UPLC 
coupled to ESI-MS was able to separate and quantify heparin/heparan sulfate 
disaccharides in under 5 minutes with heparin from porcine intestine, bovine intestine, 
and bovine kidney yielding different disaccharide compositional profiles [99]. However, 
few studies exist for the characterization of intact LMWH or UFH. Patel et al. developed 
a powerful isocratic reverse phase HPLC technique capable of developing high 
resolution fingerprints of LMWHs using both UV-vis and evaporative light scattering 
detection (ELSD) under optimized conditions. Buffer concentration, pH, proportion of 
acetonitrile, and the type and concentration of ion pairing agents were varied to optimize 
separation. Incredibly, the reverse phase technique allowed for baseline separation of 
many peaks in enoxaparin samples previously fractionated by size exclusion 
chromatography.  Such baseline resolution as yielded by this two stage separation is 
typically very difficult to obtain and would  facilitate LC-MS analysis of individual peaks, 
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giving detailed insight into the elusive structural subtleties of LMWHs [100]. Doneanu et 
al. produced the most highly resolved fingerprint of LMWH ever obtained using reverse 
phase ion pairing UPLC coupled to quadrapole time of flight mass spectrometry. The 
resolutive capabilities of UPLC and the analytical prowess of MS come together to yield 
a total ion chromatogram of tinzaparin with over 50 peaks [101]. Both of these 
techniques are capable of analyzing LMWHs in unprecedented detail, but are very 
sensitive run buffer composition and may require the use of highly complex and 
expensive equipment in the case of UPLC-MS. 
 Strong anion exchange HPLC has become one of the most effective means of 
detecting oversulfated contaminants in UFH.  Trehy et al. separated OSCS and DS from 
UFH using a polymer based SAX-HPLC column and achieved a separation far superior 
to the initial FDA method. Using UV detection, it is one of the most sensitive methods 
for detecting OSCS published to date with an LOD of 6.2 µg/ml (0.03% of 20 mg/ml 
UFH solution) [102]. The method was further developed to detect a variety of GAGS 
including CS, hyaluronic acid, oversulfated hyaluronic acid, and OSDS with elution time 
being largely dependent on the degree of sulfation of each GAG [103]. Weak anion 
exchange chromatography has yielded similar results [104]. The protocol’s sensitivity 
and resolution as well as the relative abundance of HPLC systems had led to the SAX-
HPLC method’s adoption in place of the CE protocol in the FDA and USP standards 
[46]. 
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Figure 1.1 Representative structures of glycosaminoglycans. A) Fully oversulfated 
chondroitin sulfate B) Chondroitin-6-sulfate C) Chondroitin-4-sulfate D) Dermatan 
sulfate E) Unfractionated heparin. 
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Figure 1.2: Representative structures of low molecular weight heparins. The 
brands listed are available in the USA. 
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Figure 1.3: Diagram of capillary zone electrophoresis. A) normal polarity, B) reverse  
polarity. Adapted from Dantuluri et al [67]. 
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Capillary Electrophoretic Fingerprinting of Low Molecular Weight 
Heparins 
 
2.1 Background 
A large number of biophysical techniques have been used to characterize 
heparins. Gel electrophoresis, especially PAGE, has been developed to analyze 
heparin polydispersity [105-108]. while chromatography, e.g., SEC or GPC, has been 
developed to assess the molecular weight and oligomeric composition [106,108-114] 
Other chromatographic techniques, e.g., reverse-phase, ion-pairing and strong anion 
exchange, have been used to prepare heparin oligosaccharides as well as perform 
oligosaccharide compositional analysis [36,92,115-120]. NMR spectroscopy has also 
been used to assess saccharide composition and sulfation pattern, while being 
especially useful for identifying certain non-native structures [41,121-123]. Two-
dimensional diffusion ordered spectroscopy has also been reported for detecting OSCS 
in LMWH preparations [124]. Recently, tandem liquid chromatography-mass 
spectrometry (LC-MS) has been exploited to perform sequence analysis on relatively 
purified preparations of oligosaccharide [94,125-129]. Reverse- phase-ion-pairing ultra 
high performance liquid chromatography-MS (UPLC-MS) yielded a spectacularly 
resolved total ion chromatogram fingerprint of tinzaparin, though such hyphenated 
methods require intricate equipment and skilled operators making difficult to implement 
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for routine use [101]. While these results represent significant achievements in the 
analysis of LMWH, the sheer complexity of these mixtures necessitate the further 
development of robust, consistent, and high resolution techniques.  
A technique that has gained widespread acceptance in LMWH and heparin 
oligosaccharides analysis is capillary electrophoresis (CE). The earliest application of 
CE for disaccharide compositional analysis of LMWHs [76-77,130] has now been 
modified to protocols with much better sensitivity and resolving power [131-132]. A 
significant improvement in sensitivity of CE detection has been pre-column labeling with 
chromophores or fluorophores [78,133]. Further advances in CE applicability have been 
the development of a tandem CE–MS system for elucidating structural information 
[134]. Unfortunately, these powerful approaches work on essentially pure 
oligosaccharides, enzymatically depolymerized samples, or mixtures of smaller heparin 
chains. Additionally, none of the methods is particularly suitable for assessing LMWH 
preparations on a routine basis. More importantly, the absence of a rapid and simple 
biophysical protocol for monitoring product quality is a major impediment for identifying 
LMWHs complications. We sought to develop a CE method that can be employed in 
high resolution fingerprinting of LMWH batches. Our hypothesis was that alkyl 
polyamines would be able to interact with the highly sulfated heparin chains, resulting in 
a highly resolved, formulation specific electrophoretic signature. We successfully 
established low cost, extremely simple, and robust CE method to fingerprint intact 
LMWHs that is especially useful for assessing product identity, quality, and batch-to-
batch variability. 
2.2 Experimental Procedures 
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2.2.1 Chemicals and Electrophoresis Supplies 
 Enoxaparin (LovenoxTM, 40 mg syringes, Lot # 094480) and tinzaparin 
(InnohepTM, 2 mL, 20,000U vial, Lot # DB1586) were purchased from VCU Medical 
Center Department of Pharmacy Services, Richmond, VA. Two different Sigma LMWH 
preparations (ID# H8537, lot #043K10261; and ID# H3400, lot 102K0673) from Sigma 
(St. Louis, MO.)  2-Aminoacridone (AMAC) and sodium cyanoborohydride were also 
purchased from Sigma (St. Louis, MO). Linear and cyclic polyamines were from either 
Aldrich (St. Louis, MO) or Acros (Geel, Belgium) All other reagents/chemicals were 
analytical grade and purchased from either Fisher (Fair Lawn, NJ) or Sigma-Aldrich (St. 
Louis, MO). Fused silica capillaries were purchased from Beckman-Coulter (Fullerton, 
CA). 
2.2.2 AMAC-Labeling of Low Molecular Weight Heparins  
The labeling of oligosaccharides at the reducing terminus with 2-aminoacridone 
has been described extensively in the literature [35-37]. An essentially equivalent 
protocol was followed herein. Briefly, clinically available enoxaparin and tinzaparin were 
dialyzed extensively against deionized water (MWCO 500) to eliminate excipients and 
lyophilized to obtain a solid. Sigma LMWH (ID# H3400) was obtained in solid form and 
used as such. Solid LMWH (10–15 mg) and sodium cyanoborohydride (25 mg) were 
dissolved in 560 µL of deionized water and mixed with a solution of AMAC (4 mg) 
dissolved in 158 µL of 85% (v/v) acetic acid:DMSO. The mixture was allowed to 
incubate at 37°C for 16 hours, then dialyzed against deionized water to remove free, 
unreacted AMAC, and lyophilized. The solid so obtained was dissolved in deionized 
water containing 10% DMSO (v/v) at 10 mg/mL and stored at -78°C until use. 
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2.2.3. Capillary Electrophoresis of Low Molecular Weight Heparins  
 CE was performed using a 75 µm fused silica capillary (40 cm to the detector 
window) installed in a Beckman-Coulter P/ACE MDQ capillary electrophoresis system. 
A fresh capillary was activated using 5 min flushes each of 1 M NaOH, deionized water, 
1 M H3PO4, and deionized water in sequence, while between each runs the flush time 
was reduced to 30 sec with a final run buffer flush of 2 min.  Under optimal fingerprinting 
conditions, the stock solution of a LMWH was diluted nearly 10-fold with 10% 
DMSO/water for injection into the capillary. CE run buffers used included 50 mM sodium 
phosphate buffer at pH 2.3 and 100 mM ammonium formate buffer, pH 3.5. Each 
contained 10% DMSO and appropriate resolving agent at the desired concentration. 
Every CE run was performed with fresh 1 mL buffer vials. The temperature of the 
capillary was maintained at 15°C and the run current was held constant at -75 µA under 
optimal fingerprinting conditions. AMAC-labeled LMWH was injected for 15 sec at 1 PSI 
giving a total injection amount of 150 ng and an injection volume of ~ 5–10 % of the total 
capillary volume. Electrophoresis was monitored at 254 nm with a data collection rate of 
4 Hz.  Limit of detection (LOD) and limit of quantitation (LOQ) was taken to be 3 and 10 
standard deviations above the average baseline in the region where LMWH was 
located, as defined in the literature [135].  Deviations from these conditions are noted in 
the text or figure captions. Unless specified otherwise, the Sigma LMWH used is ID# 
H3400 and enoxaparin is lot #94480. 
2.3 Results and Discussion 
2.3.1 Linear Alkyl Polyamines Resolve Electrophoretic Profile of LMWHs  
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Analysis of unfragmented, intact LMWHs is challenging because of polydispersity 
and microheterogeneity, which are major impediments to resolution despite the power 
of CE. Typically, a wide peak with few features is observed for intact LMWH samples in 
normal as well as reverse polarity implying that the mixture of the millions of species 
cannot be resolved (figure 2.1A) [136-138]. Recently, Ramasamy et al. [80] and Patel 
et al. [81] attempted to fingerprint LMWH using a bare fused silica capillary under 
reverse polarity conditions. Both groups reported an essentially broad LMWH peak 
consisting of few shoulders in the peak front. To devise a more robust method for 
assessing product identity and quality, we reasoned that the presence of certain 
polycationic agents (figure 2.2), which modify the effective charge density of the highly 
sulfated polymeric chains in a structure-dependent manner, will generate a 
characteristic fingerprint pattern in CE of intact LMWHs.  
Two clinically used LMWHs, enoxaparin (LovenoxTM) and tinzaparin (InnohepTM), 
and one LMWH from Sigma were chosen. To aid detection, each LMWH was 
reductively coupled with 2-aminoacridone (AMAC) on the reducing end. CE of AMAC-
labeled tinzaparin in 50 mM sodium phosphate buffer containing 10 % DMSO at pH 2.3 
gave an unsymmetrical broad peak between 16 and 24 min (figure 2.1A), supporting 
previous results on other LMWHs [80-81].  However, in the presence of 100 µM 
tetraethylenepentamine (4EP), a linear molecule containing five basic nitrogens 
separated by ethylene groups, the broad peak showed much longer migration time and 
displayed multiple components. Enoxaparin also exhibited a peak with few features in 
the absence of RA but was well resolved with 100 µM 4EP (figure 2.1B). Sigma LMWH 
featured a number of distinguishable peaks between 20 and 26 minutes but none were 
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baseline resolved. The addition of 50 µM 5EH transformed it into a highly resolved 
fingerprint (figure 2.1C). Among the several buffers investigated, 50 mM sodium 
phosphate (pH 2.3) and 100 mM ammonium formate (pH 3.5) (figure 2.3), provided 
optimal resolution without compromising sensitivity and speed of analysis. These results 
suggest that interaction with linear polyamines, which assume a polycationic nature in 
strongly acidic conditions, dramatically alters the electrophoretic mobility of LMWH 
chains. More importantly, the multiple peaks observed suggest that structurally different 
LMWH chains are affected to different extents. 
A wide ranging set of electrophoretic conditions were explored in acquiring useful 
LMWH fingerprints. Temperature was varied from 15 to 35°C, voltage from 5 to 25 kV, 
and capillary diameter from 50 to 75 µm. 15°C, -75 µA constant current, and 75 µM 
capillary ID were chosen for the consistency of migration times, minimization of noise 
and joule heating, and strong signal. 20 and 50 mM phosphate buffers ranging from pH 
2.17 to 3.5 were explored with the 50 mM buffer being used for later runs. 20 mM 
sodium citrate at pH 3.15 yielded LMWH peaks with excessive noise. Normal polarity 
conditions were explored with ~ pH 7 phosphate and HEPES buffers without success. 
Early in the project, it was noted that AMAC labeled LMWH tended to settle to the 
bottom of the sample vial over time. This is largely caused by tendency of the 
hydrophobic AMAC labels to aggregate in aqueous solutions, resulting in current 
irregularities and inconsistent electropherograms (figure 2.4). Acetonitrile, methanol, 
and DMSO were explored as sample additives to remedy this. A 10% DMSO additive 
proved to be the most effective additive as it disrupted the aggregation caused by the 
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hydrophobic label. DMSO had a remarkably favorable effect on run to run consistency 
and was used in all subsequent experiments. 
2.3.2 Fingerprinting Pattern Depends on the Structure of the Resolving Agent  
To assess whether the structure of the resolving agent affects the resolution of 
LMWHs, we screened several cyclic and linear polyamines (figure 2.2). We reasoned 
that the cyclic amines would present a dense cationic scaffold for possible interaction 
with closely knit polyanionic domains in LMWHs, while the linear amines would favor 
recognition of longer cationic domains. Also, linear polyamines containing either two-, 
three- or four-carbon spacers between nitrogen atoms (figure 2.2) were investigated to 
assess recognition of saccharide domains with different charge densities. 
Figure 2.5 shows the electrophoretic profile of enoxaparin in 50 mM sodium 
phosphate buffer, pH 2.3, in the presence of 125 µM concentration of either SPM, 4EP 
or 5EH. As the number of nitrogen atoms increase (SPM < 4EP < 5EH), the resolving 
agent is able to interact with enoxaparin better resulting in slower migration times. 
Sigma LMWH behaves in a similar manner (figure 2.6). Tinzaparin also follows this 
pattern, but reacts much more strongly with 5EH and weakly with SPM. This indicates 
that tinzaparin is much more sensitive than enoxaparin and sigma LMWH to the charge 
density on resolving agents (figure 2.7). This suggests that structural domains in the 
chains of the two groups of LMWHs are different. 
Although both 3ET and SPD (figure 2.2) contain four basic nitrogens, the former 
weakly resolved enoxaparin, while SPD was virtually ineffective at concentrations as 
high as 500 µM. Cyclic polyamines 3AN and 4AD were also completely ineffective. 
Likewise, polybrene, a longer cationic polymer, was also not effective (figure 2.8). This 
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suggests that fingerprinting is not a general property of all polyamines. More 
importantly, optimal distribution of basic nitrogens and chain length is necessary for 
good fingerprinting pattern. 
The fingerprint resolution is highly sensitive to not only the structure of the 
resolving agent, but also its concentration. More specifically, the linear resolving agents, 
e.g., SPM, 4EP, and 5EH displayed a narrow range of concentrations that gave the best 
resolution. For example, 125 µM 5EH baseline resolves the Sigma LMWH fingerprint 
over a long period of time (figure 2.5), meaning that further increases in resolving agent 
concentration would only extend the run time while providing little added resolution. The 
same is not true for enoxaparin (figure 2.6), suggesting  that the fingerprint pattern is 
characteristic with respect to both the LMWH and the resolving agent. 
It is important to note that several peaks are baseline resolved in the fingerprint 
pattern with 5EH, especially in the region of 22 to 30 min (figure 2.5). It is likely that use 
of laser-induced fluorescence would enhance sensitivity that would allow for the 
decrease of LMWH concentration, potentially allowing for a fully baseline-resolved 
fingerprint pattern. Baseline resolution also indicates that analysis of enoxaparin using 
CE-MS may be possible under compatible run conditions (ammonium formate). 
2.3.3 Different LMWHs Display Different Fingerprint Patterns 
To assess whether the fingerprint pattern is characteristic of individual LMWHs, 
we compared CE runs of enoxaparin, tinzaparin and Sigma LMWH in the presence of 
50 µM 4EP at pH 2.3 (figure 2.9). Each LMWH shows a characteristic fingerprint 
pattern defined primarily by the extent of interaction with the resolving agent. Whereas 
enoxaparin displays prominent peaks at 25 and 30 min, Sigma LMWH is devoid of the 
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pattern at ~30 min. In contrast, both these patterns are absent in tinzaparin. Also, 
tinzaparin displays much lower resolution than enoxaparin and Sigma LMWH. 
Equivalent results were observed for other resolving agents including SPM and 5EH 
(not shown). These fingerprint patterns are highly reproducible with notably low intra-
day (figure 2.10A). The variability in migration time was investigated in more detail for 
several resolving agents by selecting a prominent peak from the sample (data not 
shown). It was observed that the protocol yields an average migration time variability of 
21 seconds, which suggests the possibility of automated comparative analysis. With 
respect to inter-day reproducibility, the overall pattern and migration time of two 
enoxaparin fingerprints appeared consistant  (figure 2.10B), though a more detailed 
analysis would involve several sets of runs over a period of weeks. In the absence of 
resolving agent, the electrophoretic response displayed good linearity over a wide range 
concentration with a measured limit of detection and quantitation of 140±23 and 290±47 
µg/mL, respectively (see figure 2.11 and Table 2.1). These limits are not as good as 
expected and it is likely that the use of higher sensitivity chromo- or fluorophores or 
laser-induced detection may improve sensitivity. Overall, the results indicate that 
fingerprinting pattern, especially with multiple resolving agents, and the stability of 
electropherograms could greatly help identify and quantitate individual LMWHs. We 
believe that the quality and consistency of these fingerprints will prove useful in batch to 
batch analysis of LMWHs. 
2.4 Conclusions and Significance 
Our results show that LMWHs can be readily fingerprinted using a simple 
capillary electrophoretic protocol. The protocol uses readily available chemicals, is 
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rapid, and is highly reproducible in producing distinctive fingerprint patterns. It can be 
exploited for identifying intact LMWHs, monitoring product quality and for checking 
batch to batch variability. Although the resolution achieved using a single resolving 
agent is sufficient, the power of fingerprinting might be expanded with multiple resolving 
agents or with a mixture of resolving agents. This is especially important considering 
that a number of LMWHs are being rapidly introduced in the world market [139]. 
Agent 5EH was found to be especially good at resolving enoxaparin and Sigma LMWH 
into several baseline-resolved peaks. It is likely that full baseline-resolution will become 
possible with selected modifications to the protocol, e.g., use of laser-induced 
fluorescence. This will enable detailed sequence analysis of nearly all LMWH chains 
through tandem CE-MS/MS approaches. A major advantage of the MS-based analysis 
is the possibility of identifying the proportion of LMWH chains containing the high-affinity 
pentasaccharide sequence, which governs anticoagulant activity in vivo [140]. Likewise, 
it is likely that the CE-MS/MS approach will become useful in deciphering heparin 
structure – activity relationships in areas other than coagulation. 
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Table 2.1: Limit of Detection and Limit of Quantitation for Enoxaparin. 
 
 Absorbance (× 106 ) Concentration 
 (AU) (µg/mL) 
Average Noise 261 ± 42a - 
Limit of Detection 387 ± 62b 143 ± 23c 
Limit of Quantitation 681 ± 109d 290 ± 47c 
 
aSeveral blank runs were recorded and the noise in the baseline corresponding to the 
enoxaparin peak was analyzed to obtain the average noise height and its standard 
deviation. bRepresents 3×SD over the baseline. cObtained using the linear regression 
described in Figure 11. dRepresents 10×SD over the baseline. 
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Figure 2.1:  Linear alkyl polyamines turn nearly featureless peaks into highly 
resolved fingerprints.  A) Tinzaparin with and without 100 µM 4EP, B) Enoxaparin with 
and without 100 µM 4EP, and C) Sigma LMWH with and without 50 µM 5EH. Peaks 
marked with “x” are sudden disturbances due to bubble formation during the 
electrophoretic run. 
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Figure 2.2:  The structures of alkyl polyamines screened for fingerprinting 
LMWHs. 
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Figure 2.3:  Enoxaparin is effectively fingerprinted by 100 µM 4EP in 100 mM 
ammonium formate. 
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Figure 2.4:  Back to back unlabeled Sigma LMWH (H8537) runs. Buffer contained 49 
µM SPM with no DMSO in the sample and buffer.  Run conditions: 20 mM sodium 
phosphate pH 3.3, 10 kv constant voltage, 25°C constant temperature. 
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Figure 2.5:  Sigma LMWH fingerprints with 125 µM SPM, 4EP, and 5EH 
respectively. Peaks marked with “x” are sudden disturbances due to bubble formation 
during the electrophoretic run. 
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Figure 2.6:  Enoxaparin fingerprints with 125 µM SPM, 4EP, and 5EH respectively. 
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Figure 2.7:  Tinzaparin fingerprints with 125 µM SPM, 4EP, and 5EH respectively. 
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Figure 2.8:  Sigma LMWH (H8537) with two concentrations of polybrene buffer 
additive.  Run conditions:  20 mM sodium phosphate pH 3.5 with 10% DMSO, 15 kv 
constant voltage.  
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Figure 2.9:  Enoxaparin, Sigma LMWH, and tinzaparin fingerprints with 125 µM 
4EP. Peaks marked with “x” are sudden disturbances due to bubble formation during 
the electrophoretic run. 
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Figure 2.10: A)  Same day runs of Sigma LMWH with 125 µM SPM.  B)  Different 
day runs of enoxaparin with 75 µM 5EH. Peaks marked with “x” are sudden 
disturbances due to bubble formation during the run. 
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Figure 2.11:  Absorption vs. enoxaparin concentration plot demonstrating the 
dependence of peak height on the amount of labeled LMWH.  The equation 
obtained from the linear regression was used to calculate the LOD and LOQ (see Table 
1). 
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Resolution of Full Length Glycosaminoglycans 
 
3.1 Introduction 
The fingerprinting of LMWHs suggested the possibility of the same with longer 
GAGs such as UFH.  The sheer complexity of these mixtures makes their separation 
and characterization a difficult endeavor. Yet, the development of a reliable, high 
resolution fingerprinting protocol would be highly useful for a number of reasons.  First, 
UFH is taken from animal sources, meaning that their synthesis may be  affected by the 
environmental conditions in which the host lived. Fingerprinting would allow for 
detecting variation among lots of heparin and ensuring a consistent patient response 
[2]. Second, UFH has pharmacological properties far beyond its anticoagulant activity 
due to interactions with numerous proteins [141]. High resolution fingerprinting of UFH 
would aid in the discovery of specific sugar sequences responsible for this activity.  
Finally, the OSCS-heparin contamination crisis has highlighted the necessity for 
techniques capable of detecting unwanted contaminants as numerous protocols have 
appeared in the literature [26,48]. A full discussion of the issues surrounding the 
characterization of UFH can be found in Chapter 1. 
This chapter details our efforts to use the linear polyamines to resolve and 
fingerprint UFH and CS.  Conditions explored included wide variations in sample 
concentrations, buffer salt, and additives. Novel resolving agents were also explored 
 48 
including poly amino acids, protamine sulfate, polybrene, and massive polyamidoamine 
dendrimers. These results were expected to provide insight into the nature of the 
interaction between positively charged small molecules and complex GAGs. This in turn 
will prove useful structural and functional analysis of heterogeneous polysaccharide 
mixtures. 
We also explored the potential of our resolving agents in identifying OSCS 
contamination of UFH. As detailed in chapter 1, this is important for the purity of the 
drug and most importantly the safety of patients. While other CE protocols have been 
developed, we have found that 5EH provides a wider separation of the two than has 
been published. With improvements in sensitivity, this may become a useful technique 
in the analysis of UFH purity. 
3.2 Methods 
3.2.1 Materials 
UFH lot 405492 from Abraxis Pharmaceuticals (Schaumburg, IL) was purchased 
from the Department of Pharmacy Services at Virginia Commonwealth University Health 
Systems. UFH lot 026K1554 was purchased from Sigma-Aldrich (St. Louis, MO).  2-
Aminoacridone (AMAC), 2-aminoanthraquinone, 2-amino-3-hydroxyanthraquinone, CS 
(chondroitin sulfate A, lot # 038K1276), Polyamidoamino dendrimer generation 0 
(PAMAM#0), generation 1 (PAMAM#1), polybrene, protamine sulfate, pyridine, sulfur 
trioxide pyridine,and dibasic sodium phosphate were purchased from Sigma-Aldrich (St. 
Louis, MO). DMSO and hydrochloric acid was purchased from Fisher Scientific 
(Pittsburgh, PA). Pentaethylenehexamine (5EH), tetraethylenepentamine (4EP), and 
spermine (SPM) were purchased from Acros Organics (Geel, Belgium). Fused silica 
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capillary (75 µm inner diameter) was purchased from Microsolv Corporation (Eatontown, 
NJ). Sodium cyanoborohydride and decamethonium iodide were purchased from TCI 
America (Portland, OR). G-10 was purchased from GE-healthcare (United Kingdom). 
3.2.2 Labeling of GAGs 
A representative labeling procedure involved dissolving 100 mg of CS in 800 µL of high 
purity water and 8 mg of AMAC in 800 µL of a 17:3 solution of  water and incubation 
DMSO/Acetic Acid.  The AMAC was then added to the dissolved UFH and the solutions 
were allowed to incubate at 37°C for 18-24 hours, followed by the addition of 320 mg of 
sodium cyanoborohydride in 350 µL water for approximately 6 more hours. The free 
AMAC was filtered out by a sephadex G-10 column and liopholyzed. Anthraquinone  
(AMAQ) based labels underwent a similar procedure to AMAC. UFH was labeled by a 
similar procedure to CS. 
3.2.3 Oversulfation of CS 
OSCS was synthesized from CS previously labeled with 2-aminoacridone. in a 
manner similar to that reported in the literature [43]. Briefly, AMAC-labeled CS was 
converted to a triethylamine salt using a AG 50W-X8 cation exchange column followed 
by titration to pH 5 with triethylamine. 100 mg CS and 2.5 g sulfur trioxide – pyridine 
complex were dissolved in 8 ml of anhydrous DMF and stirred at 50°C for 1 h. The 
sodium salt was regenerated by precipitation by adding cold ethanol saturated with 
sodium acetate as described in the literature [43]. 
3.2.4 Capillary Electrophoresis 
CE was performed on a Beckman-Coulter P/ACE MDQ capillary electrophoresis 
instrument using 75 and 100 µm inner diameter fused silica capillaries.  The capillary 
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was rinsed with 0.5 M sodium hydroxide, water, 0.5 M phosphoric acid, and water for 2 
minutes each at the beginning of each round of CE runs and was briefly rinsed 
periodically during the day afterwards. The exact run conditions often varied between 
experiments and are noted in the caption of each figure or in the text. 
3.3 Results 
3.3.1 Fingerprinting of Unfractionated Heparin. 
Initial efforts to develop high resolution fingerprints using the same conditions as 
LMWH as described in chapter 1 were unsuccessful.  Figure 3.1 shows 
electropherograms of 30 mg/ml Sigma-Aldrich UFH with increasing concentrations of 
5EH. 25 µM 5EH merely resulted in the compression and sharpening of the main peak 
body, but higher concentrations produced a scattered peak pattern. The peaks acquired 
resembled the build up of air bubbles in the capillary due to joule heating, though the  
capillary temperature was set at 15°C. As the 50 µM runs indicate, the peaks are not 
reproducible from run to run, meaning they are not useful as fingerprints (figure 3.1b). 
The peaks seen did not translate into a usable fingerprint. Raising the concentration of 
5EH to 150 µM further increases the number of peaks indicating that there is a vigorous 
interaction taking place but in an erratic manner. Decreasing the concentration of UFH 
to 3 mg/ml of Sigma UFH  resulted in a noticeable change in the sensitivity of the GAG 
to 5EH, though it was not suitable as a fingerprint.  20 µM 5EH provided numerous 
peaks comparable to what 100-200 µM 5EH would do at much higher concentrations of 
UFH as displayed in figure 3.2. This indicates that there is likely a large number of sites 
for 5EH to saturate on UFH. A batch of clinically used UFH made by Abraxis 
Pharmaceuticals yielded the same results (not shown). Increasing the buffer 
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concentration from 20 to 50 mM sodium phosphate and reducing the concentration of 
Sigma UFH to 1 mg/ml yielded results was expected to have a moderating effect on 
5EH binding and further decrease the number of possible sites as this was considered a 
possible reason for the erratic profiles. However, results were similar to that obtained 
previously though with greater sensitivity to 5EH as seen in figure 3.3. Since 
aggregation was a major problem in developing consistent LMWH fingerprints, it was 
thought that increasing the DMSO concentration by 50-100% would prevent 
aggregation that may occur with UFH. 100 mM NaCl was added to the buffer as the 
DMSO tended to suppress the voltage at constant current. The addition of DMSO 
eliminated the peaks (figure 3.4). The addition of 20 mM triethylamine to 30 mM 
phosphate buffer with 10% DMSO produced a multi-featured fingerprint of 15 mg/ml 
Abraxis UFH in the presence of 50 µM 5EH (figure 3.5). It was hoped that adding large 
amounts of triethylamine would have a stabilizing effect on the polyamine UFH-
interaction, but it did not aid in developing useful fingerprints as the profiles acquired 
were not reproducible. 
Buffer systems based on salts other than sodium phosphate were also explored 
as changes the interactions of different electrolytes with both 5EH and UFH could affect 
how the two interacted with each other. 10 mg/ml of Sigma Aldrich UFH was not 
successfully fingerprinted when pH 2.75 50 mM sodium citrate. Changing the organic 
additive to 5% methanol yielded similar results (not shown). 100 mM ammonium 
formate pH 3.46, while successfully used to fingerprint LMWH in chapter 2 (figure 2.3) 
yielded fingerprints resembling that of sodium phosphate buffer (not shown). 
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5EH proved unable to predictably fingerprint UFH under any set of run conditions 
performed in a manner similar to those used for LMWH. A novel approach to this 
problem was needed. 25 µM 5EH was incubated with the Abraxis UFH sample 
overnight at room temperature to slow and stabilize the 5EH-UFH equilibrium.  CE was 
then performed with 25 µM 5EH in the buffer in typical fashion. The result was the most 
consistent UFH electropherograms acquired, with three back to back runs displaying 
notable similarities (figure 3.6). Even so, they did not display the reproducibility needed 
for a fingerprint useful for quality control and assurance. Runs at controlled temperature 
incubations of 37°C yielded similar results. 
The failure of 5EH as an effective agent prompted the exploration of other 
polycationic compounds as means of resolution. 4EP and SPM were successful with 
LMWH but failed with UFH, with 4EP profiles resembling that of 5EH and SPM showing 
no resolutive capability (figure 3.7). It was thought that longer polycationic compounds 
would interact differently with UFH than 5EH, creating a stable interaction and a 
reproducible fingerprint. Poly-L-lysine with an average molecular weight of 4200 gave 
inconsistent results, but often resulted in a large amount of peak compression with little 
resolution (figure 3.8). Poly-L-lysine mixtures of higher average molecular weight along 
with poly-L-arginine mixtures proved useless as resolving agents. The quaternized, 
polydisperse mixtures polybrene and protamine sulfate were explored in varying mixed 
proportions. Like the overnight 5EH incubation results, this showed a somewhat higher 
run to run consistency than usual, but failed to develop useful fingerprints (figure 3.9). 
PAMAM#1 looked to be a promising agent simply because of its large size and 
abundance of charges like polybrene, but was also a homogeneous compound. Results 
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were very similar to 5EH in that the profile was not the same from one run to the next 
(figure 3.10-3.11). 
3.3.2 Fingerprinting of Chondroitin Sulfate 
Like heparin, CS is a glycosaminoglycan with many physiologic actions and an 
astonishingly high degree of heterogeneity and polydispersity [6,142]. Thus, CS was 
expected to behave similarly to UFH in the presence of polyamines.  This however, was 
not the case as 5EH displayed little ability to interact with CS at 200 µM and had no 
resolutive capabilities with 800 µM 4EP (not shown). CS has a lower density of sulfate 
groups when compared to UFH (0.95 vs 2.4 sulfates per disaccharides, respectively). It 
is likely that there is not enough sulfate groups present on CS to effect the same 
response to 5EH that UFH does [143]. Poly-L-lysine provided resolution of CS (figure 
3.12), but this could not be reproduced. Difficulties were even more prominent with 
polybrene.  The most reproducible electrophoretic profiles for CS were obtained using 
PAMAM #1.  Figures 3.13 show that PAMAM #1 was able to generate surprisingly 
reproducible profiles of CS at 15 µM. Unfortunately, this was not consistent from day to 
day as subsequent runs lacked the resolution and repeatability desired for a fingerprint. 
As with UFH, no set of conditions explored resulted in repeatable, high resolution 
fingerprints of CS. 
3.3.3 Separation of Oversulfated Chondroitin Sulfate from Unfractionated Heparin 
While several CE protocols available for detecting oversulfated contaminants in 
UFH [45,46,84], we sought to use linear alkyl polyamines to improve on their resolution. 
Initial results CE results were confirmatory of the higher degree of sulfation pattern on 
OSCS when compared to CS (figure 3.14a-b). Both OSCS and UFH displayed affinity 
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for 40 µM 5EH at a sample concentration of 20 mg/ml, but yielded dramatically different 
profiles.  OSCS showed a compressed peak that migrated very little, but UFH displayed 
its characteristic noisy pattern.  Since the two peak bodies came out at different times, it 
was thought that UFH and OSCS would be easily separated in a mixture (figure 
3.14c,e). However, this was not the case as UFH-OSCS mixtures of varying proportions 
were inseparable. In fact, only a single peak body was present where there should have 
been two of them (figure 3.15).  The addition of 5EH to a mixture of UFH and OSCS 
likely causes aggregation of the two polysaccharides.  However, upon sharly reducing 
the sample concentration, the results are dramatically different.  Figure 3.16a-b 
displays UFH and OSCS electropherograms eluting separately as previously seen, with 
both GAGs having a sample concentration of 0.5 mg/ml and 15 µM 5EH in the run 
buffer. When combined to form a 1 mg/ml GAG mixture of 50% UFH and 50% OSCS, a 
wide separation of 10-15 minutes separation was observed (figure 3.16c). In 
comparison to other CE protocols, none have shown such a separation between OSCS 
and UFH. It is notable that the UFH migrated faster when mixed with OSCS than when 
alone. It is possible that OSCS sequesters a large proportion of 5EH and cause UFH to  
come out sooner than otherwise due to the reduced availability of the resolving agent. 
However, the low concentration of each GAG did not allow aggregation as seen with 20 
mg/ml GAG. Resolution time was further shortened by applying 0.3 PSI forward 
pressure and switching the polarity from normal to reverse (figure 3.16d).  This allows 
for OSCS to come out as normal while forcing UFH to come out in a narrow band of 
peaks. Unfortunately, the method suffered from an inadequate limit of detection. A 1 
mg/ml solution with 10% OSCS displayed an irregular signal from run to run. Less than 
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10% OSCS showed little if any signal.  The total GAG concentration was increased to 2 
mg/ml to remedy this, but resulted in a noticable reduction in resolution (figure 17). It is 
likely the case that the increased GAG concentration was causing an aggregation 
similar to that of the 20 mg/ml sample in figure 3.15.  If the concentration of the GAG 
were further increased, OSCS and UFH would likely become indistinguishable. 
3.4 Discussion 
The failure of UFH to be fingerprinted under any circumstances presents a 
puzzling problem.  Why do LMWHs yield useful fingerprints in the presence of resolving 
agents while UFH does not? The answer most likely involves an abnormally high 
number of specific binding sites. As chapter 4 discusses in detail, enoxaparin’s profile is 
largely due to the interaction of 5EH with high affinity sites on the GAG chain.  UFH’s 
affinity for 5EH is likely so high that a dynamic equilibrium sets in, with polyamines 
forming complexes with multiple UFH chains. This prevents the formation of a normal, 
reproducible fingerprint. Further evidence is seen in figures 3.1-3.3, where decreasing 
the UFH sample concentration 10-fold increases its response to 5EH in a noticeable 
manner. This indicates that whatever binding sites are available on UFH are not 
completely saturated at the concentrations of resolving agents used for fingerprinting. 
Further evidence of this phenomenon is clearly seen in the OSCS-UFH studies where 
the two components are only resolvable when their concentration is low. At higher 
concentrations, polyamines act as a “glue” that holds them together.  It is highly likely 
that such aggregation is occurring between UFH molecules in the presence of 5EH 
even when OSCS is absent. 
 56 
Alternatively, it is possible that the “noise” seen in most profiles is due to joule 
heating resulting from the high sulfate density of UFH and the concentration of 
polyamines. However, the data suggests otherwise. The LMWH trials in chapter 2 do 
not show such noisy profiles though they also contain a high density of sulfates. The 
fact 20 and 50 mM sodium phosphate buffers showed similar peak patterns indicates 
that higher ionic strength is not the cause of the irregular profiles (figures 3.2-3.3). 
Rather, it is due a tighter interaction of UFH with the resolving agents. 
The best solution to the problem of UFH would be to use laser-induced 
fluorescence detection as this is much more sensitive than UV.  This would allow the 
concentration of UFH to be reduced dramatically, possibly eliminating aggregation and 
reducing the number of binding sites.  Such improvements would also allow for lowering 
the limit of detection of OSCS, making it a potentially viable method. 
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Figure 3.1: Same day fingerprints of UFH in the presence of 5EH. A) 0 and 25 µM 
5EH; B) 4 repeated runs of 50 µM 5EH; C) 150 µM 5EH. Sample: 30 mg/ml Sigma UFH 
026k1554 in 10% DMSO; Buffer: 20 mM sodium phosphate 10% DMSO pH 2.3; 254 nm 
detection; Injection: 15 seconds@1psi; temperature: 15°C; Separation: 110 µA 
Capillary: 100 µm ID. 
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Figure 3.2: Same day fingerprints of reduced concentration UFH in the presence 
of 20 µM 5EH. Sample: 3 mg/ml Sigma UFH 026k1554 in 10% DMSO; Buffer: 20 mM 
sodium phosphate 10% DMSO pH 2.3; 254 nm detection; temperature: 15°C; Injection: 
15 seconds@1psi; Separation: 110 µA; Capillary: 100 µm ID. 
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Figure 3.3: Same day fingerprints of 1 mg/ml UFH in the presence of 5EH.  A) 3 µM 
5EH, B) 6 µM 5EH. Sample: 1 mg/ml Sigma UFH 026K1554 in 10% DMSO; Buffer: 50 
mM NaPi pH 2.3; 254 nm detection; Injection: 10 seconds@1.5psi; temperature: 15°C; 
Separation: 110 µA; Capillary: 100 µm ID. 
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Figure 3.4: Same day fingerprints of 3 mg/ml Sigma UFH in 15 µM 5EH with 
differing buffer compositions.  A) 20 mM sodium phosphate pH 2.3 10% DMSO, B) 
20 mM sodium phosphate, 100 mM NaCl, 17.5% DMSO. Sample: 3 mg/ml Sigma UFH 
026k1554 in 10% DMSO; 254 nm detection; Injection: 15 seconds@1psi; Separation: 
110 µA; Capillary: 100 µm ID. 
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Figure 3.5: An attempt to fingerprint UFH with 50 µM 5EH and 20 mM 
triethylamine. Sample: 15 mg/ml Abraxis UFH 405492 10% DMSO; Buffer: 30 mM 
sodium phosphate 20 mM triethylamine pH 2.3 10% DMSO; 254 nm detection; 
Injection: 10 seconds @ 1.5 psi; temperature: 15°C; Separation: 10 kV; Capillary: 75 µm 
ID. 
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Figure 3.6: UFH sample that was incubated with 25 µM 5EH overnight. Three 
consecutive runs were performed. Sample: 10 mg/ml Abraxis UFH 405492 10% DMSO 
25 µM 5EH; Buffer: 50 mM sodium phosphate pH 2.3 10% DMSO; 254 nm detection; 
Injection: 8s@1psi; temperature: 25°C; Separation: 10 kV; Capillary: 75 µm ID. 
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Figure 3.7: SPM and 4EP used in the resolution of UFH. A) 50 µM SPM, B) 50 µM 
4EP. Sample: 2 mg/ml Sigma UFH 026K1554 10% DMSO; Buffer: 50 mM sodium 
phosphate pH 2.3 10% DMSO; 254 nm detection; Injection: 8 seconds@1psi; 
temperature: 15°C; Separation: 100 µA; Capillary: 75 µm ID. 
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Figure 3.8: Attempt to resolve UFH with poly-L-lysine (mean MW: 4200). A) 2.5 µM 
PLL, B) 5 µM PLL, C) 7.5 µM PLL, D) 10 µM PLL. Sample: 10 mg/ml Abraxis UFH 
405492 10% DMSO 25 µM 5EH; Buffer: 50 mM sodium phosphate pH 2.3 10% DMSO; 
254 nm detection; Injection: 10 seconds@1.5psi; temperature: 25°C; Separation: 10 kV; 
Capillary: 75 µm ID. 
 
 
 
 
 
 
 
 
 65 
0
0.02
0.04
0.06
0.08
0.1
0.12
0 10 20 30 40 50
A
b
s
o
rb
a
n
c
e
 a
t 
2
5
4
 n
m
Time  (min)
C)
A)
B)
A
b
s
o
rb
a
n
c
e
 a
t 
2
5
4
 n
m
 
Figure 3.9: Attempt to resolve UFH a mixture of polybrene and protamine. A) No 
agent, B) 15 µg/ml polybrene+5 µg/ml protamine #1 C) 15 µg/ml polybrene+5 µg/ml 
protamine #1. Sample: 20 mg/ml Abraxis UFH 405492 10% DMSO; Buffer: 50 mM 
sodium phosphate pH 2.3 10% DMSO; 254 nm detection; Injection: 8 seconds@1psi; 
temperature: 15°C; Separation: 10 kV; Capillary: 75 µm ID. 
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Figure 3.10: The structure of polyamidoamide #1 (PAMAM #1). 
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Figure 3.11: Attempt to resolve UFH with PAMAM#1. A) No agent, B) 40 µM 
PAMAM#1, C) 100 µM PAMAM#1. Sample: 15 mg/ml Abraxis UFH 405492 10% 
DMSO; Buffer: 50 mM sodium phosphate pH 2.3 10% DMSO; 254 nm detection; 
Injection: 10 seconds@1.5psi; temperature: 15°C; Separation: 15 kV; Capillary: 75 µm 
ID. 
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Figure 3.12: Attempt to resolve CS with poly-L-lysine (average MW: 4200) and 
polybrene. A) No agent, B) 25 µM poly-L-lysine, C) 25 µg/ml polybrene. Sample: CS 
038K1276 10% DMSO; Buffer: 50 mM sodium phosphate pH 2.3 10% DMSO; 254 nm 
detection; Injection: 8 seconds@1 psi; temperature: 15°C; Separation: 14 kV; Capillary: 
75 µm ID. 
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Figure 3.13: Attempt to resolve CS with back to back runs with 15 µM PAMAM #1. 
A) 15 µM PAMAM #1, B) 15 µM PAMAM #1. Sample: CS 038K1276 10% DMSO; 
Buffer: 50 mM sodium phosphate pH 2.3 10% DMSO; 254 nm detection; Injection: 8 
seconds@1 psi; temperature: 15°C; Separation: 14 kV; Capillary: 75 µm ID. 
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Figure 3.14: A comparison of CS, OSCS and UFH. All GAGs labeled with 
athraquinone and dissolved in 10% DMSO for CE.  A) 9 mg/ml CS with no agent, B) 
10 mg/ml OSCS with no agent, C) 20 mg/ml OSCS with 40 µM 5EH, D) 20 mg/ml Acros 
UFH lot B0126660 with no agent, E) 20 mg/ml Acros UFH lot B0126660 with 40 µM 
5EH. Buffer: 50 mM sodium phosphate pH 2.3 10% DMSO; 300 nm detection; Injection: 
8 seconds@1psi; temperature: 15°C; Separation: 85µA ; Capillary: 75 µm ID. 
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Figure 3.15: A comparison of  three mixtures of OSCS and UFH. All GAGs labeled 
with 2-aminoanthraquinone and dissolved in 10% DMSO to a combined concentration 
of 20 mg/ml for CE. UFH lot: B0126660. A) 20% UFH 80% OSCS, B) 60 % UFH 40% 
OSCS, C) 80% UFH, 20% OSCS. Buffer: 50 mM sodium phosphate pH 2.3 10% 
DMSO; 300 nm detection; Injection: 8 seconds@1psi; temperature: 15°C; Separation: 
85µA ; Capillary: 75 µm ID. 
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Figure 3.16: A comparison of  UFH, OSCS, and a mixture of the two. All GAGs 
labeled with 2-aminoacridoine and dissolved in 10% DMSO. UFH lot: 026K1554. A) 0.5 
mg/ml UFH, 15 µM 5EH B) 0.5 mg/ml OSCS, 15 µM 5EH , C) 1 mg/ml – 50% UFH, 50% 
OSCS, 15 µM 5EH. D) 1 mg/ml – 50% UFH, 50% OSCS, 15 µM 5EH w/ 0.3 PSI forward 
pressure and normal polarity switch at 30 minutes. Buffer: 50 mM sodium phosphate pH 
2.3 10% DMSO; 254 nm detection; Injection: 8 seconds@1psi; temperature: 15°C; 
Separation: 85µA ; Capillary: 75 µm ID. 
 73 
0
0.01
0.02
20 30 40 50
A
b
s
o
rb
a
n
c
e
 a
t 
2
5
4
 n
m
Time  (min)
A)
B)
 
Figure 3.17: Back to back electropherograms of a 2 mg/ml GAG solution with 75% 
UFH and 25% OSCS in the presence of 20 µM 5EH. Buffer: 50 mM sodium phosphate 
pH 2.3; 254 nm detection; Injection: 8 seconds@1psi; temperature: 15°C; Separation: 
85 µA; Capillary: 75 µm ID. 
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Insights into the Interaction of Linear Polyalkylamines with Low 
Molecular Weight Heparins and Glycosaminoglycans Using Capillary 
Electrophoresis 
4.1 Introduction 
GAGs are unparalleled among biomolecules in terms of their massive structural 
complexity, intricate and variable biosynthetic preparation, and astonishingly difficult 
structural, biochemical and biophysical characterization. This difficulty has inspired a 
large number of biophysical methods for analysis of different GAGs [68]. Further, a 
number of protocols relying on HPLC [100,102], NMR [45,55,144], CE [86,88], and a 
combination of techniques [51] have been developed for detecting UFH contaminants. 
We described a CE protocol that fingerprints LMWHs in chapter 2. Linear polyamines 
(figure 2.2) were used as resolving agents to produce fingerprint patterns in reverse 
polarity, open-tube CE from essentially featureless and unresolved profiles. These 
fingerprints were characteristic of the LMWH being analyzed, which afforded a major 
advance in profiling differences among LMWHs could prove suitable in assessing the 
batch-to-batch variability. 
In this chapter, we address the question of why linear polyalkylamines are 
effective in fingerprinting LMWHs and whether these could be used in profiling other 
GAGs. Our work suggests that CE profile of GAGs such as DS, CS, OSCS and heparin 
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in the presence of polyalkylamines can be used to understand the composition of these 
complex mixtures. This property arises from differential recognition of micro-structures 
present in GAGs, which enable high affinity recognition of highly sulfated chains. These 
results are important because small molecule probes of GAGs are critically needed to 
aid in structural and functional analysis. 
4.2 Methods 
4.2.1 Materials 
Enoxaparin (Lovenox, 40 mg syringe Lot # 09438) was purchased from the 
Department of Pharmacy Services at Virginia Commonwealth University Health 
Systems.  2-Aminoacridone (AMAC), CS (chondroitin sulfate A, lot # 038K1276), DS (lot 
# 118K1217), and dibasic sodium phosphate were purchased from Sigma-Aldrich (St. 
Louis, MO). DMSO and hydrochloric acid was purchased from Fisher Scientific 
(Pittsburgh, PA). Pentaethylenehexamine (5EH), tetraethylenepentamine (4EP), and 
spermine (SPM) were purchased from Acros Organics (Geel, Belgium) and used as 
received. Fused silica capillary (75 µM inner diameter) was purchased from Microsolv 
Corporation (Eatontown, NJ). Sodium cyanoborohydride and decamethonium iodide 
were purchased from TCI America (Portland, OR). Oligosaccharide species were 
purchased from Idruron (Manchest, UK). 
4.2.2 Chromogenic Labeling of GAGs 
  AMAC labeling of enoxaparin was performed in a manner similar to that reported 
in the literature so as to enable detection of polymeric chains [145]. Briefly, LMWH (40 
mg) was dissolved in 250 µL water, while AMAC (10 mg) was dissolved in 400 µL of 
DMSO:acetic acid (17:3 v/v). The two solutions were mixed, followed by the addition of 
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200 µL of sodium cyanoborohydride (100 mg) in water. The reaction was allowed to 
proceed for 16 hours at 37°C. The AMAC-labeled enoxaparin from the reaction mixture 
was purified via a G-10 column, the fractions lyophilized, and solid stored at 4°C until 
use. Samples for electrophoresis were dissolved in 10% DMSO and water just before 
analysis. Similar procedures were used for preparing AMAC-labeled UFH, CS, DS, and 
OSCS. 
4.2.3 Capillary Electrophoresis  
CE was performed using a Beckman-Coulter P/ACE MDQ capillary 
electrophoresis system using a 50 cm long fused silica capillary (40 cm to detector 
window, 75 µ ID). The electrophoresis buffer was composed of 50 mM sodium 
phosphate, pH 2.3, containing 10% DMSO. The capillary was flushed with 
electrophoresis buffer for two minutes, followed by injection of the analyte for 8 seconds 
at 1 psi. AMAC-labeled GAGs were dissolved in 10% DMSO to prevent aggregation. 
Separations were performed at either constant current (~85 µA) or voltage (~10 kV), 
temperature of 15°C and monitored at a wavelength of 254 nm. The capillary was 
periodically flushed with 0.5 N NaOH, 0.5 M H3PO4, and deionized water to maintain its 
resolution capability. GAG fingerprints were acquired with SPM, 5EH, 4EP and DM 
(figure 2.2, 4.1). For the enoxaparin affinity studies, typically, 8-13 different 
concentrations of each resolving agent were studied within a day. Each concentration 
was studied at least 3 to 5 times to ensure repeatability. 
For polyamine oligosaccharide affinity studies, a constant voltage of 15 kv was 
used at 230 nm detection. 
4.2.4 Data Analysis 
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The affinities of LMWH and glycosaminoglycan components for linear 
polyalkylamines were measured from the change in electrophoretic mobility (µep) as a 
function of the concentration of the resolving agent. The µep values were calculated 
using equation 1, which is a modified form of that used in the literature [146]. 
 
 
          (Equation 1) 
 
 
In this equation, Le is the effective length of the capillary to the detector window, 
peak migration time is represented by tmig, and V is the applied constant voltage. This 
equation does not include a reference migration term, i.e., the migration time of neutral 
marker for reducing run-to-run variations, as reported in the literature [146], because a 
neutral marker does not migrate under the strongly acidic conditions, which suppress 
electro-osmotic force. To reduce incidental run-to-run variations under reverse polarity 
conditions, the average current for each run (66-72 µA range) was used to normalize 
migration times and mobilities. 
The affinity (KD) of polyalkylamine for GAG components was calculated using 
equation 2, which is an adaptation of the Scatchard equation. In this equation, ∆µep is 
the change of electrophoretic mobility of a given CE peak in the presence of resolving 
agent (RA) as compared to that in its absence (µ0
ep.) Because the resolved peaks are 
not distinguishable without the RA, the mobility of a peak at the start of the 
∆µep =
V
Lt
Le
Tmig
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electropherogram in the absence of RA (~15 min) was used as µ0
ep. KD, the equilibrium 
dissociation constant, was calculated from the slope of the plot. 
  
   
  (Equation 2) 
   
4.3 Results 
4.3.1 The Interaction of Linear Polyamines With Various Glycosaminoglycans 
In chapter 2, linear polyalkylamines were used to fingerprint enoxaparin, 
tinzaparin and a generic LMWH [19]. Positively charged polyalkylamines (figure 2.2) 
recognize a collection of negatively charged sulfate groups on LMWH chain resulting in 
a fingerprint pattern. Because each LMWH is structurally distinct, its CE profile in the 
presence of RA was found to be characteristic of its composition (figure 2.9). In a 
manner similar to LMWHs, other GAGs are also structurally distinct in terms of 
constituent residues, inter-residue linkages, and the overall three dimensional 
organization of anionic groups. We reasoned that these features should induce 
differential recognition of GAGs by linear polyalkylamines. To test this hypothesis, we 
subjected UFH, CS and DS, the three most common available GAGs, to the 
fingerprinting protocol developed for LMWHs.  This allowed us to discern why RA’s 
interact with sulfated polysaccharides based on what is known about the structures of 
the GAGs studied. 
∆µep ∆µepmax
[RA] KD
= - +
KD
∆µep
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Figure 4.2A shows CE profiles of AMAC-labeled UFH, CS and DS in the 
presence and absence of 5EH, a representative RA. All three polymeric GAGs gave 
broad peaks in the absence of 5EH. UFH eluted in about 20 mins, while CS and DS 
eluted between 26 – 28 mins, which was in accordance with their negative charge 
density. In the presence of 200 µM 5EH, a concentration found to readily fingerprint 
enoxaparin, the broad CS peak shifted to about 30 min indicating weak interaction with 
the RA that is not sufficient to induce fingerprinting. In contrast, UFH was essentially 
fully resolved into multiple peaks in the presence of 200 µM 5EH (figure 2A) indicating 
dramatically different interaction. Interestingly, even 10 µM 5EH resolved UFH into 
multiple peaks suggesting a high affinity interaction between the two molecules (not 
shown). DS, on the other hand, was separated into two groups of peaks – a broad peak 
resembling CS’s broad profile and a cluster of sharp peaks resembling the UFH profile. 
This dual distribution profile could be transformed into single multi-peak profile at higher  
RA levels, e.g., 500 µM 5EH suggesting that the distribution into two major components 
is simply a function of affinity-governed equilibrium. To test whether CS also exhibits 
this phenomenon, higher 5EH levels were screened (up to 1000 µM). Although the 
migration time of CS gradually increased, no resolution was observed (not shown) 
suggesting that the fundamental structural difference between CS and DS is sensed 
extremely well by these linear polyalkylamines. 
Changing the resolving agent to 4EP, a polyamine with potentially one less 
positive charge at pH 2.3 gave results similar to those obtained with 5EH, though the 
concentration of 4EP was four times that of 5EH (figure 4.2B). Thus, at 800 µM 4EP, 
UFH and DS resolved into multiple peaks (figure 4.2B). In contrast, CS continued to 
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display broad peak profile. Higher concentrations of 4EP were necessary to induce 
resolution possibly because of its lower affinity for the polymeric polyanions. 
Despite the wide difference in the interaction profile of polymeric GAGs with 
linear polyalkylamines, it was difficult to truly fingerprint the UFH and DS. Considerable 
variation in peak widths, shapes and number was observed between runs for UFH as 
reported in chapter 3 and for DS. We theorize that as the UFH:RA multimers resolve, a 
dynamic equilibrium is established, which rapidly changes the electrophoretic mobilities 
resulting in changes in peak pattern between runs. DS was less susceptible to variation 
than UFH, but this changed at higher concentrations of RA. Yet overall, the observation 
that UFH and DS, but not CS, interact and resolve well with linear polyalkylamines 
indicates that these small molecules could be used as probes for direct analysis of 
GAGs. 
4.3.2 Fingerprints of Low Molecular Weight Heparins Arises From a Two-site 
Interaction Phenomenon 
Previous work with LMWH fingerprinting suggested that 5EH was the best RA 
among those tested (chapter 2). The above analysis of full-length GAGs showed that 
fingerprinting was not possible for CS, was minimal for DS, and unsuitable for UFH 
based on their interactions with the RAs. This implied that linear polyalkylamines 
selectively fingerprint LMWHs, i.e., shorter polysaccharide chains with high sulfate 
density. Between different linear polyalkylamines, however, a certain polycationic 
charge density was necessary as decamethonium (figure 4.1) failed to resolve any 
LMWH (as well as other GAGs) at concentrations as high 1000 µM (figure 4.3). To 
assess the fundamental basis for this phenomenon, fingerprinting profiles of enoxaparin 
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were studied with increasing concentrations of 5EH (figure 4.4). The fingerprints were 
highly reproducible with a day-to-day variability of < 5% (data not shown). In the 
absence of a mass spectrometric assignment of the peaks observed in the fingerprints, 
which is expected to be difficult due to lack of baseline resolution, ascertaining the 
change in migration time of individual LMWH chains is nearly impossible. However, the 
peak shape pattern remains the same as the concentration of 5EH increases. This was 
also found for 4EP (figure 4.5) as well as SPM (figure 4.6), enabling the monitoring of 
few peaks with high fidelity over a large range of RA concentration. To assess how the 
RAs interact with LMWHs chains, we selected two of these high fidelity, representative 
peaks for 5EH and 4EP, and one peak for SPM. It is important to recognize that the 
selected peaks do not necessarily represent one specific LMWH chain; in fact, these 
most probably represent many different chains, except with reasonably similar structural 
features that induce co-migration. Thus, for a mixture containing millions of species, the 
selected peaks represent chains with higher proportion of structural identity. Each peak 
was studied at 8-13 concentrations and electrophoretic mobilities of the peaks were 
calculated based on standard literature reported methods. 
Figure 4.4-4.6 shows the Scatchard analysis of the interaction of 5EH, 4EP, and 
SPM with select peaks of enoxaparin as just described. The 5EH and SPM profiles 
show a biphasic interaction phenomenon for both the selected peaks. Typically, a linear 
Scatchard plot suggests single site binding, while a biphasic plot indicates two binding 
sites with sufficiently different affinities [147]. The observation of two binding modes for 
molecules as simple and small as 5EH and 4EP is interesting as well as challenging. 
Based on first principles, these LMWH peaks would be expected to display an average 
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single-site interaction phenomenon because the peaks are not completely 
homogeneous and the equilibrium status within the capillary would be dynamic. The 
observation of a biphasic binding mode suggests that 5EH and 4EP recognize selected 
chains of LMWHs in a highly specific manner. Similar results were obtained for SPM 
and enoxaparin, though with only a single peak and with a larger amount of error 
compared to 5EH and 4EP at the high affinity concentration (figure 4.6B). Thus, the 
similarity across the three RAs studied suggests that this characteristic is likely to be 
generally valid for most LMWH chains. 
4.3.3 Fingerprinting Arises from Differential Interactions of Different Low 
Molecular Weight Heparin Chains 
To gain quantitative information regarding the reason for the observation of 
fingerprints, we analyzed the observed biphasic profile as arising from two LMWH – RA 
equilibria that are not co-operatively linked. Typically, such biphasic profiles arise when 
the affinities are sufficiently distinct and thus can be analyzed using the Scatchard 
equation on each arm of the profile. Application of equation 2 to each arm of the 5EH – 
enoxaparin biphasic profile gave KD values of 123 µM and 0.024 µM for peak 1, and 
53.8 µM and <10 nM for peak 2 under the conditions of CE experiment (table 1.1). This 
corresponds to differences of 5125- and 5400-fold between the two affinities for both 
peaks 1 and 2, respectively. Thus, 5EH displays exceptionally strong affinity for some 
LMWH chains (nM), while interacting with perhaps most chains with much lower affinity 
(µM). The high affinity interactions most probably correspond to specific recognition of 
LMWH chains through the formation of one or more hydrogen bonds, while the low 
affinity interaction probably arises from a generalized non-specific Coulombic ion pairing 
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[148]. We believe that the high affinity interactions are the primary reason that 
polyalkylamines are able to generate fingerprints since they cause chains with similar 
binding profiles to group together to form peaks from which average affinity values can 
be obtained. 
The affinity difference remains intact for the other two RAs also. Table 4.1 lists 
the affinities measured for the selected peaks using Scatchard analysis. Both 4EP and 
SPM demonstrate a weaker interaction profile with LMWH chains as compared to that 
with 5EH. The high affinity interaction ranged from 0.74 µM to 5.2 µM, which is 
approximately 74 – 520-fold weaker than the high affinity interaction observed for 5EH. 
In contrast, the low affinity interactions for 4EP and SPM were 267, 308 and 414 µM, 
which implies a much weaker 4.9 – 7.7-fold effect. Thus, while the high affinity 
interactions are significantly different between the RAs, the low affinity interactions are 
fairly similar. These differences in the interactions, especially those of the high affinity 
type, generate differences in the fingerprinting profiles with each RA. 
An important derivation of these observations is that it should be possible to 
develop powerful RAs for specific fingerprinting of these highly complex GAGs. For 
example, the affinity of LMWH chains increase with the number of positively charged 
amines on the RA. While the strength of the low affinity interaction does not decrease 
precipitously, the high affinity interaction is dramatically weakened through a change 
from 5EH and 4EP (table 4.1). Hence, it can be expected that longer polyalkylamines, 
perhaps linear and/or branched, would resolve LMWHs or GAGs better. It may even 
become possible to induce baseline resolution for direct structural analysis using 
tandem ESI-MS. 
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4.3.4 Tetra, Hexa, and Decasacharide Fingerprints do not Show Two Site Binding 
Profiles 
 Theoretically, oligosaccharides of the same number of sugars would be more 
homogeneous and thus easier to analyze than LMWH, UFH, or other GAGs as 
structural diversity would be dramatically lower. To shed further light on the interaction 
of polycations with GAGs, the interaction purchased heparin oligosaccharides with the 
RA’s was also studied. For hexa and decasaccharide, the electropherograms displayed 
remarkable homogeneity.  Upon the addition of 5EH however, both profiles split into 
multiple peaks. This was especially prominent with decasaccharide (figure 4.7). 
Tetrasaccharide yielded similar results with 5EH and several other resolving agents (not 
shown). Such results were expected since oligosaccharides, while simpler than LMWH, 
are still not homogeneous with variation of uronic acid conformation and sulfation 
pattern that only increases with length.  Affinity studies were unsuccessful to excessive 
peak blending at lower concentrations and difficulty in tracking specific peaks across 
higher concentrations. It was nearly impossible to identify peaks with certainty. 
4.4 Discussion 
Structural characterization of GAG chains is challenging because of their 
massive structural complexity. This work presents a rather simple protocol of resolving a 
group of GAGs through the use of linear polyalkylamines under strongly acidic 
electrophoretic conditions. The interaction of these agents with full-length heparin was 
found to be unusually strong. In fact, the affinity of UFH for linear polyalkylamines is 
likely to be lower than that of LMWH, which was found to be in the range of 10 nM. 
Structurally, UFH is a linear helical molecule [149] that presents its sulfate groups on 
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the surface resulting in greater number of polycationic recognition motifs than possible 
for LMWHs. Further, a three-fold longer heparin chain affords a major statistical 
advantage resulting in higher affinity for the RAs.  
Unfortunately, UFH’s significantly higher affinity did not translate into a 
fingerprinting advantage. Although UFH could be resolved into multiple peaks, the CE 
profile is not reproducible as noted for LMWHs [19]. The likely reason for this 
phenomenon is the possibility of high-affinity induced dynamic equilibrium between 
multiple equivalent binding sites on UFH chains for linear polyalkylamines and the 
formation bridges between GAG chains as discussed in chapter 3. While the dynamic 
equilibrium during electrophoresis is also present for LMWHs, the reduced affinity of 
RAs engineers an averaging effect resulting in high reproducibility. An alternative, less 
likely, explanation is that LMWHs and UFH are structurally distinct. The fact that 
LMWHs are derived from UFH from either chemical, enzymatic, or chromatographic 
means implies that the microstructures of the two species are likely to be similar. Yet, 
the dramatically distinct response of LMWHs and UFH to linear polyalkylamines is 
interesting and worth investigating. If either of the two hypotheses regarding UFH – 
linear polyalkylamine interaction is true, longer chains of RAs, e.g., a polyamine three 
times longer than 5EH, can be expected to fingerprint UFH at appropriately lower 
concentrations. Such polyamines are known in the literature [150-151] and may offer 
fingerprinting advantage, but may also carry cytotoxic and/or carcinogenic adverse 
effects [152-153].  
Fingerprinting of LMWHs is highly dependent on the structure of the RA as 
demonstrated here as well in chapter 2. Affinity measurements performed here 
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demonstrate that optimal chain length and positive charge density are crucial for 
achieving resolution. Comparison of structures shows that UFH/LMWH, DS, and CS 
contain an average of 2.4, 1.2, and 0.95 sulfate groups per disaccharide, respectively, 
in their representative sequences [143]. This suggests that linear polyalkylamines 
studied here are effective when sulfate charge density is more than one per 
disaccharide (most carboxylates are expected to be protonated at pH 2.3). Yet, the 
ability of these RAs to interact with GAGs is not just dependent on sulfate charge 
density. OSCS, which is expected to possess sulfate density much greater than 1.2, 
does not interact strongly with linear polyalkylamines. This suggests an intricate 
structural component to these interactions. 
Finally, the fundamental insight into the basis for fingerprinting of LMWHs by 
linear polyalkylamine-based resolving agents will be of value to the design of advanced 
resolving agents. Compounds with varying charge density, electrophoretic mobility, and 
conformation flexibility could be designed and screened. The possibility of baseline 
resolution in these profiles will facilitate direct mass spectrometric analysis for deduction 
of heparin sequences as well as for chemoinformatic profiling. 
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Table 4.1: Affinities of Selected Enoxaparin Chains for Resolving Agents. 
 Peak #
a 
High Affinity 
Interaction 
(µM)b 
Low Affinity 
Interaction 
(µM)b 
Ratio of High to Low 
Affinity 
5EH 
1 0.024 123 5125 
2 <0.01 54 >5400 
     
4EP 
1 1.9 312 165 
2 0.74 263 355 
     
SPM 1 5.2 417 80 
 
aPeaks are identified in Figure 4. bThe affinities of peaks were measured through 
Scatchard analysis. See Materials and Methods section. 
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Figure 4.1: The structure of decamethonium. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 89 
 
 
Figure 4.2: Interaction of linear polyalkylamines with glycosaminoglycans. 
Resolution of CS, DS, and UFH with 200 µM 5EH (A) and 800 µM 4EP (B). CE was 
performed in reverse polarity mode in 50 mM sodium phosphate buffer, pH 2.3, 
containing 10% DMSO at 10 kV and 15°C. A 75 µM (i.d.) capillary, which as 50 cm to 
the detector window, was used for these experiments. The profiles have been offset to 
enhance clarity. 
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Figure 4.3: Fingerprints  Enoxaparin, UFH, CS, and DS (A-D) with 
decamethonium.  Upper diagram (A): without resolving agents. Lower 
diagram (B): with 500 µM decamethonium. decamethonium. 
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Figure 4.4: Affinity Data for 5EH and Enoxaparin. A) Resolution of LMWH with 
increasing concentrations of 5EH. CE was performed in 50 mM sodium phosphate 
buffer, pH 2.3 containing 10% DMSO and fixed concentration of the RA at 10 kV and 
15°C. Only selected profiles, offset to enhance clarity, are shown. Typically 3 – 4 
experiments were performed at each concentration to ensure high reproducibility. The 
observed fingerprint patterns are highly consistent for LMWHs. Individual peaks, e.g., 1 
and 2, can be followed as a function of RA concentration. See text for details. B) 
Scatchard analysis of mobility data acquired from peak 1 (square) and peak (2). 
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Figure 4.5: Affinity Data for 4EP and Enoxaparin. A) Resolution of LMWH with 
increasing concentrations of 4EP. Conditions were the same as in figure 4. The 
observed fingerprint patterns are highly consistent for LMWHs. Individual peaks, e.g., 1 
and 2, can be followed as a function of RA concentration. See text for details. 
B) Scatchard analysis of mobility data acquired from peak 1 (square) and peak 2 
(circle). 
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Figure 4.6: Affinity Data for SPM and Enoxaparin. A) Resolution of LMWH with 
increasing concentrations of SPM. Conditions were the same as in figure 4. 
B) Scatchard analysis of mobility data acquired from the indicated peak. 
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Figure 4.7: Fingerprints of decasaccharide and hexasaccharide using 5EH. The 
concentrations used are A) 0 µM, B) 40 µM, C) 100 µM, D) 250 µM. 
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A Batch to Batch Capillary Electrophoretic Analysis of Low Molecular 
Weight Heparins 
 
5.1 Background 
The issue of biosimilar LMWHs issue has come to prominence in recent years 
with the branded products approaching the end of their patent life and generics entering 
clinic around the world. Yet the sheer complexity of these products means that 
developing an equivalent product  would prove very difficult. Differences between brand 
and generic LMWHs have been noted especially with regards to LovenoxTM and generic 
enoxaparin products available in other countries [139]. The fundamental question is this: 
can a true generic formulation of LMWH be structurally identified with reasonable 
degree of certainty? Alternatively, can a prospective LMWH be reliably differentiated at 
an early stage from that used in the clinic? 
In July of 2010, the FDA approved the first LMWH for use in the US as a generic 
equivalent of enoxaparin. While substantial in vivo and in vitro tests were performed to 
establish equivalence, structural equivalence was limited to molecular weight 
distribution and 1,6-anhydromannose ring proportion [31,32]. Considering the 
complexity of LMWHs, establishing biosimilarity with just two structural techniques is a 
dangerous proposition. Yet, structural analysis of intact LMWHs is a challenging 
endeavor. A wide range of electrophoretic, chromatographic, spectroscopic and mass 
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spectrometric techniques have been used for heparin disaccharide and 
oligosaccharides [76-78,101,155], but few protocols exist for intact LMWHs [101, 155-
158]. 
Patel et al. developed a reverse phase HPLC method using tetrabutylammonium 
hydroxide as an ion pairing agent that produced highly resolved chromatograms of 
intact enoxaparin and dalteparin that displayed notably different profiles [100]. Excellent 
resolution of a mixture of oligosaccharides with degree of polymerization ranging from 6 
to 22 was achieved using reverse phase-ion pairing UPLC coupled to mass 
spectrometry, which was extended to generate a tinzaparin chromatogram of over 50 
peaks [101]. Outside of these methods, advanced multi-dimensional NMR spectroscopy 
and advanced electrospray ionization-MS methods have been developed [41,85,123], 
but their wide-spread applicability is doubtful. 
Having developed a protocol for characterizing LMWHs with linear 
alkylpolyamines and capillary electrophoresis, we sought to assess whether generic 
enoxaparin is structurally equivalent to Lovenox as analyzed by our high-resolution CE 
fingerprinting protocol. Fingerprinting using multiple resolving agents shows that both 
generic and brand name enoxaparin behave in an essentially identical manner across a 
range of conditions suggesting essentially identical structural composition. More 
specifically, our protocol reveals that two batches of brand name enoxaparin studied are 
sufficiently different to accommodate generic enoxaparin within their realm. In contrast, 
enoxaparin and tinzaparin display widely different fingerprints suggesting that our 
fingerprinting protocol is extremely robust to rapidly assess compositional, and hence 
structural, equivalence. This work contributes to assessing the chemical equivalence of 
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LMWH formulations and lays the groundwork for evaluating future generics and brands 
expected to enter the clinic. 
 
5.2  Materials and Methods 
5.2.1  Chemicals 
LovenoxTM (Lot #15146 and #29411), generic enoxaparin (Sandoz, Lot #914690), 
and InnohepTM (Lot #DC1863 and #DC9158) were purchased from Virginia 
Commonwealth University Health Systems Pharmacy. 2-Aminoacridone (AMAC), 
DMSO, and dibasic sodium phosphate were purchased from Sigma-Aldrich (St. Louis, 
MO). Pentaethylenehexamine (5EH), tetraethylenepentamine (4EP), and spermine 
(SPM) were purchased from Acros Organics (Geel, Belgium). Fused silica capillary was 
purchased from Microsolv Corporation (Eatontown, NJ). Sodium cyanoborohydride was 
purchased from Fisher Scientific (Pittsburgh, PA). G-10 media was purchased from GE 
Healthcare (Little Chalfont, UK). Cellulose ester dialysis membranes (500-1000 
molecular weight cutoff) were purchased from Spectrum Laboratories (Rancho 
Dominguez, CA). All other chemicals and reagents were either from Sigma-Aldrich or 
Fisher. 
5.2.2  Labeling of LMWHs with Aminoacridone 
Enoxaparin and tinzaparin were labeled in a manner similar to that reported 
earlier. Briefly, 10 mg AMAC was dissolved in 860 µL of an 85% solution of 
DMSO/acetic acid and mixed with 860 µL aqueous solution containing 40-80 mg 
LMWH. The mixture was allowed to incubate for ~12 h at 37°C followed by addition of 
200 mg of sodium cyanoborohydride in water. The reaction was allowed to proceed for 
 98 
6 more hours at 37°C.  The unreacted aminoacridone was removed via a G-10 column 
and the AMAC-labeled LMWH was dialyzed against 2 liters of water for 24 hours using 
membrane with a molecular weight cutoff of 500-1000. Following three changes of 
water, the solution lyophilized to yield pure AMAC-labeled LMWH. Each preparation of 
AMAC-labeled LMWH was redissolved in water to yield a stock solution of 50 mg/ml 
and stored at -80°C until use. 
5.2.3  Capillary Electrophoresis 
CE was performed using a Beckman-Coulter P/ACE MDQ capillary 
electrophoretic system with a fused silica capillary (I.D. 75 µM) of 50 cm length and 40 
cm to the detector window. At the beginning of each day, the capillary was conditioned 
with 0.5 M sodium hydroxide, water, 0.5 M phosphoric acid, and finally water. The 
capillary was rinsed with run buffer (50 mM dibasic sodium phosphate, pH 2.3) for 2 
minutes before each run and periodically with hydroxide, acid, and water. After rinsing, 
LMWH samples were diluted to either 4 (enoxaparin) or 1 mg/ml (tinzaparin) and 
injected into the capillary for 8 s at 1 PSI. Runs were performed at a constant current of 
90 µA at a temperature of 15°C. Each run was completed four times to ensure 
reproducibility. For figure 5.8, all LMWH concentrations were 1 mg/ml. 
5.2.4  NMR Analysis of Low Molecular Weight Heparins 
1H-NMR and 13C-NMR spectroscopy was performed on a 400 MHz Bruker 
Ultrasheild plus NMR spectrometer. Unlabeled LMWH (40-50 mg) was dissolved in D2O 
and lyophilized twice to remove H2O. The sample was then re-dissolved in D2O and 
1H-
NMR spectrum acquired.  13C-NMR spectra were taken overnight using 10,000 scans 
with a line broadening factor of 10 to maximize the signal to noise ratio. 
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5.3  Results 
5.3.1  Qualitative Analysis of LMWH Fingerprints and NMR Spectra 
Following the protocol developed earlier, fingerprints of two lots of Lovenox and 
one lot of generic enoxaparin (from Sandoz) were developed using 250, 500 and 1000 
µM of three linear polyalkylamines, 5EH, 4EP and SPM, respectively. No differences 
were noted without resolving agents. Qualitatively, the fingerprints reveal striking 
similarities between the brand and generic enoxaparins as seen in figures 5.1-5.3, 
where the fingerprints have been aligned on the X-axis by designated peaks and 
expanded along the Y-axis to compensate for the lack of an internal standard and to 
enable minor peaks to be seen more easily. SPM and 4EP show the most similarities, 
while 5EH shows some variation (see close ups, figures 5.1-5.3). Figures 5.4-5.6 show 
unadjusted electropherograms of the same runs. The three batches of enoxaparin 
displayed several major peaks in the presence of 4EP and SPM, which migrated in an 
essentially identical manner (within ~1.5 min). The migration times varied consistently 
more with 5EH, especially for later peaks (~2.5 – 4 min) of lot #29411, probably due to 
the higher affinity of this resolving agent. Alternatively, lot #29411 may possess a 
slightly altered overall sulfation pattern, which measurably affects electrophoretic 
mobility. Such variation is important and can be addressed with larger sample size, 
however, this was beyond the scope of our project.  
Two batches of tinzaparin were also analyzed (generic tinzaparin is not available, 
as yet) with 1000 µM SPM and 200 µM 4EP (figure 5.7). The tinzaparin fingerprints 
were highly consistent across the batches with major peaks migrating at nearly identical 
times and no obvious difference in resolution. It is notable that at 200 µM 4EP (figure 
 100 
5.7B),  tinzaparin features “noise” peaks similar to that seen with UFH at ~45 minutes 
and beyond. Given that tinzaparin is acquired via enzymatic digestion of UFH, it is likely 
that it retains more of UFH’s basic structural features than chemically depolymerized 
LMWH and will thus behave in a similar manner. Interestingly, the “noise” peaks 
become more prominent and begin interfering with the main peak body when 
concentration of tinzaparin sample is raised. In spite of their similarities to each other, 
tinzaparin fingerprints are widely different from enoxaparin fingerprints. Figure 5.8 
shows a comparison of two tinzaparin and three enoxaparin batches in the presence of 
200 µM 4EP. Major differences in group of peaks at ~22 and ~27 min are obvious. 
Interestingly, the ‘center of gravity’ of the tinzaparin profile is significantly delayed as 
compared to enoxaparin, which may indicate an average lower charge to mass ratio.  
To assess whether such similarities and differences are picked up by 1H and 13C 
NMR spectroscopy, we recorded the spectra for all LMWH batches. While expected 
peaks such as those representing the N-acetyl protons at ~ 2-2.05 ppm were seen, 
none of the spectra demonstrated any difference for the enoxaparin or the tinzaparin 
batches (figure 5.9-12). Between enoxaparin and tinzaparin, both 1H and 13C NMR 
spectra were noted to be different, but the differences were not as obvious as revealed 
by fingerprinting protocol. This indicates that the structural heterogeneity of these 
LMWH preparations is so high that the resulting peak broadening in NMR spectra 
accommodates minor structural differences. 
5.3.2  Quantitative Analysis of LMWH Fingerprints 
To more accurately compare the LMWH fingerprints, detailed analysis was 
performed for each profile. Notable differences emerged for several peaks in terms of 
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both area and height. For example, peak 2 for enoxaparin resolved with 5EH (figure 
5.4) displayed different areas of (2.9±0.2)×106, (3.1±0.2)×106, and (1.7±0.05)×106 for 
one generic and two batches of Lovenox. Similar differences were also calculated for 
enoxaparins with 4EP and SPM (figure 5.5-5.6). However, considering the absence of 
a fixed reference in these fingerprints, such differences could possibly be explained by 
non-structural or compositional reasons. Thus, relative changes in the proportions of the 
resolved components were evaluated using peak 1 as a reference point as this would 
allow the comparison of enoxaparin lots while correcting for differences in percent 
labeling. Table 5.1 shows the ratio of area for peaks 2 as a proportion of peak 1 for 
enoxaparin fingerprints in the presence of 250 µM 5EH, resulting in values of 4.7, 6.98 
and 2.98 for generic batch 914690 and LovenoxTM 15146 and 29411 respectively.  The 
differences between these are substantial and reaches over 100% when comparing the 
brand batches to one another, differences in each ratio can be noted between the two 
batches of Lovenox. In fact, the ratios of various peaks displayed substantial variation 
across the two batches of Lovenox. Generic enoxaparin displayed ratios different from 
either Lovenox lots, but within the range defined by the two batches of the brand 
enoxaparin (see figure 5.4 and table 5.1). These conclusions remained the same when 
peak area ratios were evaluated with 4EP or SPM fingerprints (see figure 5.5-5.6 and 
table 5.2-5.3). 
5.4  Discussion 
Our earlier work on the mechanistic basis of LMWH fingerprinting indicated that 
each linear polyalkylamine studied, i.e., 5EH, 4EP and SPM, interacted with the 
polyanionic polysaccharide with high affinity (chapters 2 and 4). More importantly, a 
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biphasic interaction phenomenon was observed, thus explaining the highly specific 
fingerprint achieved with each polyalkylamine. This led to the idea that as a group these 
polybasic molecules might help identify small differences between different LMWHs and 
especially pinpoint differences between different batches of the same LMWH, if any. 
This idea is exciting because high resolution fingerprints coupled with nano-MS 
technology may provide a robust, operational platform for quick assessment of 
‘biosimilarity’ [101]. 
To our knowledge, rigorous comparison of brand and generic enoxaparin has not 
been reported in the literature, although it has been widely recognized that generic 
LMWH may be technologically difficult to achieve [139,154,159]. Our effort is the first 
bioanalytical comparison of Lovenox with its generic version. Using the three molecule 
toolbox, our analysis suggests that the two enoxaparins are remarkably similar within 
limits of experimental error. In fact, the two batches of Lovenox display greater variance 
between them for all three polyalkyamine resolving agents, which accommodates the 
generic enoxaparin reasonably well. This result is striking and appears to indicate that 
the variation in the manufacture of the brand LMWH may be sufficiently high to 
accommodate several versions of generic. 
Given that the fingerprints are the results of structure-specific interactions of the 
resolving agents with LMWH chains, the variations in the fingerprints imply detectable 
differences in the chemical composition of Lovenox from batch to batch. This difference 
is less with regard to the type of polysaccharide species and more with regard to the 
proportion of species. This work provides  a stimulus for a wider study with much higher 
sample size so as to define the limits better. Yet, whether these structural differences 
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necessarily imply functional (beneficial and adverse) differences remains unevaluated, 
although theoretically a direct correlation is predicted. 
Our study demonstrated a higher level of consistency between the two batches 
of tinzaparin studied here. More importantly, the resolution with polyalkylamines was so 
high that massive differences were evident between tinzaparin and enoxaparin. This 
was in striking contrast to one-dimensional 1H and 13C NMR spectra that failed to 
display much differences. The work, therefore, highlights the limitations of one-
dimensional NMR spectroscopy in such analysis, while showcasing the power of linear 
polyalkylamine-based CE fingerprinting. 
Finally, although limited in scope our effort provides a glimpse into the inter-batch 
variability and puts forward a robust platform for assessing structural biosimilarity of 
LMWHs. The use CE-MS could greatly expand this protocol. The bioanalytical 
fingerprinting is no substitute for clinical and epidemiological data, but could form an 
inexpensive method for rapid evaluation of ‘biosimilarity’. Considering that more generic 
LMWHs are being prepared for clinical entry, our protocol would be handy. 
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Figure 5.1:  Comparison of enoxaparin fingerprints in the presence of 250 µM 
5EH. Lot numbers from the bottom: 914690, 15146, 29411. Electropherograms have 
been aligned by peaks aligned with the peak marked by (*) for ease of comparison. Y-
values have been multiplied for optimum to increase peak height. 
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Figure 5.2:  Comparison of enoxaparin fingerprints in the presence of 500 µM 
4EP. Lot numbers from the bottom: 914690, 15146, 29411. Electropherograms have 
been aligned by peaks aligned with the peak marked by (*) for ease of comparison. Y-
values have been multiplied for optimum to increase peak height. 
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Figure 5.3:  Comparison of enoxaparin fingerprints in the presence of 1000 µM 
SPM. Lot  numbers from the bottom: 914690, 15146, 29411. Electropherograms have 
been aligned by peaks aligned with the peak marked by (*) for ease of comparison. Y-
values have been multiplied for optimum to increase peak height. 
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Figure 5.4:  Unmodified enoxaparin batch fingerprints acquired with 250 µM 5EH. 
Analysis of the highlighted and numbered peaks are seen in table 5.1. 
 
 
Table 5.1:  Peak area analysis of enoxaparin batches with 250 µM 5EH. 
Mean Stdev Mean Stdev Mean Stdev
Pk 1 63377 7267 44530 2792 59336 7739
Pk 2 297710 22649 310995 16863 176577 5099
Pk 3 274201 25475 250014 19755 144012 5355
Pk 2:1 4.70 0.90 6.98 0.82 2.98 0.47
Pk 3:1 4.33 0.90 5.61 0.80 2.43 0.41
Pk 3:2 0.92 0.16 0.80 0.11 0.82 0.05
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Figure 5.5:  Unmodified enoxaparin batch fingerprints acquired with 500 µM 4EP. 
Analysis of the highlighted and numbered peaks are seen in table 5.2. 
 
Table 5.2:  Peak area analysis of enoxaparin batches with 500 µM 4EP. 
Mean Stdev Mean Stdev Mean Stdev
Pk 1 68187 11706 36841 4653 44525 1857
Pk 2 272719 20369 251961 11216 135537 13891
Pk 3 236724 20613 235613 11080 124493 16653
Pk 4 356554 24984 275923 10681 215826 19855
Pk 2:1 4.00 0.985 6.84 1.168 3.04 0.439
Pk 3:1 3.47 0.898 6.40 1.108 2.80 0.491
Pk 3:2 0.87 0.140 0.94 0.086 0.92 0.217
Pk 4:1 5.23 1.264 7.49 1.236 4.85 0.648
Pk 4:2 1.31 0.420 1.10 0.236 1.59 0.393
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Figure 5.6:  Unmodified enoxaparin batch fingerprints acquired with 1000 µM 
SPM. Analysis of the highlighted and numbered peaks are seen in table 5.3. 
 
Table 5.3: Peak area analysis of enoxaparin batches with 1,000 µM SPM. 
Mean Stdev Mean Stdev Mean Stdev
Pk 1 79393 2768 62632 4400 61453 7766
Pk 2 41337 1299 41846 1389 33194 7514
Pk 3 242483 8371 216374 10043 141178 6794
Pk 4 109210 5231 94834 13114 115188 5279
Pk 5 457733 19401 461615 23927 296239 16357
Pk 2:1 0.52 0.03 0.67 0.07 0.54 0.19
Pk 3:1 3.05 0.21 3.45 0.40 2.30 0.40
Pk 4:1 1.38 0.11 1.51 0.32 1.87 0.32
Pk 5:1 5.77 0.45 7.37 0.90 4.82 0.88
Pk 5:2 11.07 0.82 11.03 0.94 8.92 2.51
Pk 3:2 5.87 0.39 5.17 0.41 4.25 1.17
Pk 4:3 0.45 0.04 0.44 0.08 0.82 0.08
Pk 5:3 1.89 0.15 2.13 0.21 2.10 0.22
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Figure 5.7:  Batch to batch tinzaparin comparison.  A) 1000 µM SPM, B) 200 µM 
4EP.   No adjustments made to data. 
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Figure 5:8: Tinzaparin and enoxaparin batches in the presence of 200 µM 4EP. All 
GAG concentrations 1 mg/ml.  Batches beginning with DC are tinzaparin. The data 
points have been multiplied on the Y axis to increase peak height and allow for easy 
comparisons. No adjustment made on the X-axis. 
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Figure 5:9:  1H-NMR of enoxaparin batches in D2O. 
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Figure 5:10:  13C-NMR of enoxaparin batches in D2O. A line broadening factor of 10 
was used to maximize the signal to noise ratio. 
 
 
 
 
 
 
 
 
 
 
 
 114 
 
DC9158
DC9158
 
Figure 5:11:  1H-NMR of tinzaparin batches in D2O. 
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Figure 5.12:  13C-NMR of tinzaparin batches in D2O. A line broadening factor of 10 
was used to maximize the signal to noise ratio. 
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